https://trial.medpath.com/news/cellectar-biosciences-submits-phase-1b-protocol-for-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-06-24T17:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-hu6-demonstrates-significant-liver-fat-reduction-in-phase-2-mash-trial 2025-06-24T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-roctavian-gene-therapy-shows-sustained-efficacy-after-five-years-in-severe-hemophilia-a 2025-06-24T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/favipiravir-shows-promise-against-deadly-chandipura-virus-in-preclinical-studies 2025-06-24T17:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-genomics-partners-with-alborada-institute-to-accelerate-alzheimer-s-drug-discovery-using-3d-multi-omics-platform 2025-06-24T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/mindrank-s-ai-designed-oral-glp-1-drug-achieves-10-3-weight-loss-in-phase-2b-trial 2025-06-24T16:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/neuron23-secures-96-5m-series-d-funding-as-first-patient-dosed-in-phase-2-parkinson-s-disease-trial 2025-06-24T16:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-expands-scientific-advisory-board-with-hcc-experts-as-phase-2-trial-approaches 2025-06-24T16:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/cytodyn-initiates-phase-ii-trial-of-leronlimab-in-relapsed-refractory-colorectal-cancer 2025-06-24T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-inm-901-shows-significant-anti-inflammatory-activity-in-alzheimer-s-disease-preclinical-study 2025-06-24T16:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/stuart-therapeutics-reports-mixed-phase-iii-results-for-st-100-dry-eye-treatment 2025-06-24T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/smart-soft-healthcare-s-columbo-ai-spine-assistant-receives-fda-clearance-for-enhanced-scoliosis-and-fracture-detection 2025-06-24T16:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/jb-chemicals-secures-fda-approval-for-generic-amitriptyline-depression-treatment 2025-06-24T16:14:20+00:00 hourly 0.9 https://trial.medpath.com/news/kif18a-emerges-as-promising-cancer-target-with-multiple-therapies-advancing-through-clinical-trials 2025-06-24T16:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-bioengineered-external-liver-assist-device-treats-patient-in-groundbreaking-clinical-trial 2025-06-24T16:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-initiates-phase-3-trial-of-kb803-gene-therapy-for-corneal-complications-in-dystrophic-epidermolysis-bullosa 2025-06-24T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/supercede-therapeutics-reports-promising-preclinical-data-for-novel-oral-obesity-treatment-targeting-actrii-pathway 2025-06-24T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/schott-pharma-commits-eur100-million-to-expand-ready-to-use-sterile-cartridge-manufacturing 2025-06-24T13:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/imdx-digital-pcr-platform-shows-equivalent-performance-to-ngs-in-kidney-transplant-rejection-testing 2025-06-24T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-partners-with-usp-to-enhance-quality-standards-for-monoclonal-antibody-and-gene-therapy-development 2025-06-24T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/outsee-secures-ps1-8m-seed-funding-to-advance-ai-powered-genomics-platform-for-drug-discovery 2025-06-24T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/sterotherapeutics-doses-first-patient-in-phase-2-trial-of-st-002-for-cushing-s-syndrome 2025-06-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-extends-16-year-research-partnership-with-tsinghua-university-for-three-more-years 2025-06-24T13:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-secures-2-billion-funding-deal-with-royalty-pharma-for-ras-cancer-drug-development 2025-06-24T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/brightgene-s-dual-glp-1r-gipr-agonist-bgm0504-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trial 2025-06-24T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/sonrai-analytics-partners-with-plectonic-biotech-to-advance-ai-driven-logic-gated-antibody-cancer-immunotherapies 2025-06-24T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-tevimbra-first-immuno-oncology-drug-in-india-for-lung-and-esophageal-cancer-treatment 2025-06-24T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/zambon-secures-chinese-approval-for-intravenous-fluimucil-following-successful-phase-3-trial 2025-06-24T12:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/australian-clinical-trials-test-antiviral-drugs-targeting-epstein-barr-virus-for-multiple-sclerosis-treatment 2025-06-24T12:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-lu-ag13909-receives-orphan-drug-designation-for-congenital-adrenal-hyperplasia-treatment 2025-06-24T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/her2-positive-gastric-cancer-pipeline-shows-robust-activity-with-20-companies-developing-novel-therapies 2025-06-24T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/axcelead-ddp-and-superluminal-expand-partnership-to-target-challenging-biological-mechanisms 2025-06-24T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/ema-backs-ozempic-label-expansion-for-peripheral-artery-disease-based-on-stride-trial-data 2025-06-24T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/deepecho-receives-fda-510-k-clearance-for-ai-powered-fetal-ultrasound-analysis-platform 2025-06-24T04:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/tissium-receives-fda-de-novo-authorization-for-first-atraumatic-sutureless-peripheral-nerve-repair-system 2025-06-24T04:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-therapy-expands-beyond-cancer-care-as-multi-center-studies-launch 2025-06-24T03:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-receives-south-korean-approval-for-alzheimer-s-biomarker-detection-platform 2025-06-24T03:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/implantica-completes-fda-pma-submission-for-refluxstop-device-prepares-us-manufacturing-for-gerd-treatment 2025-06-24T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-healthcare-innovations-unveils-quattrii-inhaler-technology-to-deliver-large-dose-biologics-and-mrna-therapies 2025-06-24T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-to-report-phase-2b-atopic-dermatitis-trial-results-for-novel-regulatory-t-cell-therapy 2025-06-24T01:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-to-present-pivotal-data-for-ros1-selective-inhibitor-zidesamtinib-in-advanced-lung-cancer 2025-06-24T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-advances-ai-driven-obesity-pipeline-with-myostatin-and-activin-e-antibody-therapies 2025-06-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-and-doj-complete-final-listening-session-on-drug-price-competition-reforms 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pathai-receives-fda-clearance-for-aisight-dx-digital-pathology-platform-for-primary-diagnosis 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-invests-25-million-in-adagene-s-safebody-platform-for-next-generation-cancer-immunotherapy 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tam-global-appoints-leading-cancer-immunologist-dr-francesco-marincola-as-chief-scientific-officer 2025-06-23T23:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-acting-drug-chief-jacqueline-corrigan-curay-to-retire-amid-leadership-exodus 2025-06-23T22:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/australian-government-invests-12-million-in-cardiovascular-and-diabetes-medical-technology-innovation 2025-06-23T22:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/sichuan-biokin-s-first-in-class-egfr-her3-adc-advances-to-phase-3-trials-across-multiple-cancer-types 2025-06-23T21:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-acquires-somalogic-for-425-million-to-accelerate-proteomics-and-multiomics-strategy 2025-06-23T21:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/dr-ashleys-limited-acquires-impact-biomedical-in-strategic-reverse-merger-to-accelerate-global-drug-development 2025-06-23T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/lifeplus-achieves-clinical-validation-for-revolutionary-non-invasive-glucose-and-blood-pressure-monitoring-device 2025-06-23T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-base-editing-shows-promise-for-treating-fatal-pediatric-vascular-disease-msmds 2025-06-23T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-names-charles-schoch-as-permanent-cfo-following-successful-86m-capital-raise 2025-06-23T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-completes-enrollment-in-diabetic-foot-ulcer-trial-testing-placental-derived-allograft 2025-06-23T20:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/evofem-s-phexxi-hormone-free-contraceptive-seeks-regulatory-approval-in-uae-through-strategic-partnership 2025-06-23T20:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biomedica-achieves-full-ownership-of-us-subsidiary-to-strengthen-global-gene-therapy-manufacturing-network 2025-06-23T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-guidelines-lag-behind-clinical-practice-as-oncologists-increasingly-adopt-ctdna-testing 2025-06-23T18:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/laekna-s-lae102-shows-promising-safety-profile-in-first-in-human-obesity-trial-at-ada-2025 2025-06-23T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-reaches-50-patent-milestone-with-new-epilepsy-and-nicotine-delivery-patents 2025-06-23T16:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/carisma-therapeutics-and-orthocellix-announce-25m-merger-to-advance-phase-3-knee-cartilage-therapy 2025-06-23T16:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/cure-rare-disease-advances-lgmdr9-gene-therapy-following-positive-fda-pre-ind-meeting 2025-06-23T16:55:05+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-acquires-plasma-services-group-to-strengthen-rare-disease-biomarker-supply-chain 2025-06-23T16:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-to-present-phase-2-data-for-arct-810-mrna-therapy-in-rare-genetic-disorder 2025-06-23T16:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-licenses-dual-jak-syk-inhibitor-gusacitinib-from-formation-bio-in-eur545-million-deal 2025-06-23T16:50:27+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-reports-positive-phase-2-results-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2025-06-23T16:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-submits-phase-iii-protocol-for-vafidemstat-in-borderline-personality-disorder-targeting-first-fda-approved-treatment 2025-06-23T16:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/denovo-biopharma-out-licenses-biomarker-guided-depression-drug-db104-to-taiwan-partner 2025-06-23T16:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/viromed-s-cold-plasma-technology-demonstrates-potential-to-prevent-6000-deaths-annually-from-ventilator-associated-pneumonia 2025-06-23T16:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-bone-growth-accelerator-for-spinal-fusion-surgery 2025-06-23T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/vsee-health-selected-for-nih-funded-phase-3-stroke-telerehabilitation-trial-across-29-hospitals 2025-06-23T16:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/angiodynamics-initiates-recover-av-trial-for-pulmonary-embolism-treatment-device 2025-06-23T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/altrubio-s-altb-268-shows-promise-in-preclinical-models-of-inflammatory-diseases-supporting-phase-2-uc-trial 2025-06-23T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/new-analysis-shows-radicava-ors-extends-survival-and-slows-functional-decline-in-als-patients 2025-06-23T13:39:58+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-strategies-and-adverse-event-management-transform-mcrpc-care 2025-06-23T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/monument-therapeutics-reports-positive-phase-i-results-for-novel-schizophrenia-cognitive-treatment-mt1988 2025-06-23T13:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/penn-researchers-transform-deadly-aspergillus-fungus-into-potent-anti-leukemia-drug 2025-06-23T13:14:26+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-strengthens-leadership-with-endocrinology-expert-to-advance-hypoparathyroidism-treatment 2025-06-23T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-icovamenib-shows-promise-in-combination-with-glp-1-therapies-for-type-2-diabetes 2025-06-23T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/itm-and-debiopharm-initiate-new-study-arm-for-caix-targeted-theranostic-in-clear-cell-renal-cell-carcinoma 2025-06-23T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-imp761-shows-80-t-cell-suppression-in-phase-i-autoimmune-disease-trial 2025-06-23T13:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/novadip-receives-fda-rmat-designation-for-nvd003-regenerative-therapy-in-rare-pediatric-bone-disease 2025-06-23T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/spanish-researchers-develop-dna-test-to-predict-chemotherapy-resistance-clinical-trials-set-for-2026 2025-06-23T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-alvotech-s-biosimilar-to-eylea-for-eye-disorders 2025-06-23T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-ceo-returns-to-drive-us-expansion-with-vitiligo-treatment-approval-strategy 2025-06-23T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-launches-feasibility-study-for-oral-dissolvable-film-semaglutide-delivery 2025-06-23T13:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-completes-enrollment-of-phase-3-trial-for-once-daily-oral-pah-treatment-ralinepag 2025-06-23T13:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-and-ono-pharmaceutical-form-strategic-alliance-for-povetacicept-development-in-japan-and-south-korea 2025-06-23T13:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-s-quviviq-receives-approval-in-china-for-insomnia-treatment-through-simcere-partnership 2025-06-23T10:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/progenis-pharmaceuticals-secures-mtpconnect-funding-for-novel-rna-based-type-2-diabetes-treatment 2025-06-23T08:55:42+00:00 hourly 0.9 https://trial.medpath.com/news/carmil2-gain-of-function-mutation-shows-promise-for-next-generation-cancer-immunotherapies 2025-06-23T08:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-nxt007-achieves-zero-bleeds-in-phase-i-ii-hemophilia-a-trial-advances-to-phase-iii 2025-06-23T08:54:46+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-appoints-former-horizon-cfo-aaron-cox-to-lead-strategic-transformation 2025-06-23T08:54:24+00:00 hourly 0.9 https://trial.medpath.com/news/utopia-therapeutics-secures-1-5m-for-novel-obesity-vaccine-ut009 2025-06-23T08:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/primary-biliary-cholangitis-pipeline-shows-strong-progress-with-multiple-late-stage-therapies-and-recent-fda-approvals 2025-06-23T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-secures-global-rights-to-hbm7020-bcmaxcd3-bispecific-t-cell-engager-for-autoimmune-diseases 2025-06-23T05:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/water-consumption-doubles-diabetes-remission-rates-compared-to-diet-beverages-in-clinical-study 2025-06-23T05:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-secures-100-million-partnership-with-harvard-s-gregory-verdine-to-advance-ai-driven-drug-discovery 2025-06-23T04:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/major-food-companies-eliminate-artificial-dyes-following-fda-push-and-health-concerns 2025-06-23T04:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-launches-next-generation-promarkerd-test-for-early-diabetic-kidney-disease-detection-in-us-market 2025-06-23T00:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-industry-faces-wave-of-strategic-layoffs-as-companies-prioritize-efficiency-and-pipeline-focus 2025-06-23T00:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/sonrotoclax-plus-zanubrutinib-shows-promise-in-relapsed-refractory-mantle-cell-lymphoma-with-78-response-rate 2025-06-22T21:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-mim8-shows-safe-direct-switch-from-emicizumab-in-phase-3b-hemophilia-a-trial 2025-06-22T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-once-weekly-insulin-efsitora-alfa-achieves-non-inferiority-in-phase-3-trials-reducing-injection-burden-by-300-doses-annually 2025-06-22T20:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/russia-initiates-phase-i-clinical-trial-for-enteromix-cancer-vaccine-based-on-four-non-pathogenic-viruses 2025-06-22T17:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-oral-diabetes-drug-orforglipron-shows-promise-in-phase-3-trial-offering-alternative-to-injectable-glp-1-therapies 2025-06-22T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-startup-s-urine-based-cancer-test-detects-stage-0-lung-cancer-in-hokkaido-pilot-study 2025-06-22T04:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/magellan-stem-cells-receives-tga-manufacturing-license-advancing-australia-s-cell-therapy-independence 2025-06-22T04:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lenacapavir-for-hiv-prevention-with-99-9-efficacy-but-high-cost-raises-accessibility-concerns-in-india 2025-06-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-advance-nanoscale-drug-delivery-systems-with-targeted-cell-recognition-and-biological-signal-response 2025-06-22T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/abvance-therapeutics-presents-first-human-data-on-fixed-ratio-insulin-glucagon-combination-for-type-1-diabetes 2025-06-22T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-kesimpta-shows-sustained-efficacy-in-multiple-sclerosis-patients-over-seven-years 2025-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radioligand-therapy-177lu-lu-neob-enters-clinical-testing-for-advanced-breast-cancer 2025-06-21T23:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/sai-life-sciences-completes-major-capacity-expansion-at-bidar-manufacturing-facility 2025-06-21T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-delivery-technology-aims-to-prevent-opioid-overdoses-through-controlled-release 2025-06-21T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-eptinezumab-shows-strong-efficacy-in-asian-chronic-migraine-patients-in-phase-iii-sunrise-trial 2025-06-21T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/unc-lineberger-cancer-center-leads-28-million-arpa-h-trial-to-revolutionize-metastatic-breast-cancer-treatment 2025-06-21T14:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-s-bofanglutide-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trials 2025-06-21T13:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-minimed-780g-system-shows-promise-for-type-2-diabetes-and-young-children-with-type-1-diabetes 2025-06-21T06:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/verdiva-bio-advances-once-weekly-oral-glp-1-and-amylin-therapies-for-obesity-treatment 2025-06-21T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-pharmacists-demonstrate-significant-cost-savings-and-expanded-clinical-roles-through-remote-services-and-ai-integration 2025-06-21T03:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/ema-initiates-review-of-sodium-oxybate-for-alcohol-dependence-following-efficacy-and-safety-concerns 2025-06-21T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promising-survival-rates-for-stem-cell-transplants-from-mismatched-unrelated-donors 2025-06-21T00:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-files-c-50-million-shelf-prospectus-to-advance-mdma-drug-development 2025-06-21T00:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-diabetes-drug-liraglutide-reduces-migraine-days-by-half-in-pilot-study 2025-06-21T00:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/cansinobio-launches-ipneucia-r-13-valent-pneumococcal-vaccine-optimized-for-chinese-children 2025-06-20T22:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-patent-protection-for-aflibercept-with-new-formulation-patent-against-amgen 2025-06-20T21:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-submits-ind-hold-response-to-fda-for-depression-treatment-gh001-ahead-of-schedule 2025-06-20T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-secures-100-msek-financing-to-advance-hdac-inhibitor-pipeline-for-rare-cardiovascular-and-pulmonary-diseases 2025-06-20T19:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-secures-multiple-fda-approvals-for-generic-drug-portfolio-expansion 2025-06-20T18:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/candid-therapeutics-doses-first-patients-with-novel-t-cell-engagers-for-autoimmune-diseases 2025-06-20T18:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/dutch-court-upholds-xtandi-patent-protection-blocking-generic-enzalutamide-launch-until-2028 2025-06-20T16:56:18+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-bct-unveils-automated-car-t-manufacturing-platform-delivering-12-billion-cells-in-7-8-days 2025-06-20T16:56:09+00:00 hourly 0.9 https://trial.medpath.com/news/lomond-therapeutics-receives-fda-clearance-for-phase-1-trial-of-lonitoclax-in-relapsed-refractory-aml 2025-06-20T16:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-receives-positive-chmp-opinion-for-ustekinumab-biosimilar-usymro 2025-06-20T16:53:39+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-biotech-raises-5-9-million-to-advance-annamycin-through-phase-3-aml-trial 2025-06-20T16:52:23+00:00 hourly 0.9 https://trial.medpath.com/news/onco360-partners-with-deciphera-to-distribute-qinlock-for-advanced-gist-patients 2025-06-20T16:14:58+00:00 hourly 0.9 https://trial.medpath.com/news/perceptive-discovery-and-pfizer-launch-fibre-consortium-to-advance-fibrosis-drug-development-through-advanced-imaging 2025-06-20T16:14:43+00:00 hourly 0.9 https://trial.medpath.com/news/shine-technologies-lutetium-177-isotope-ilumira-reaches-global-milestone-with-19-country-distribution-network 2025-06-20T16:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-recommends-approval-of-partner-therapeutics-imreplys-for-acute-radiation-syndrome-treatment 2025-06-20T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-biotherapeutics-pivots-to-bitcoin-treasury-strategy-following-clinical-trial-failures 2025-06-20T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuno-cure-partners-with-pharmajet-to-advance-hiv-therapeutic-dna-vaccine-using-needle-free-delivery-technology 2025-06-20T15:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/valirx-secures-ps16-million-licensing-deal-for-repurposed-risperidone-cancer-therapy-val401 2025-06-20T14:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/european-phase-ii-trial-tests-simple-home-intervention-to-prevent-heart-failure-in-cancer-survivors 2025-06-20T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-first-risk-prediction-model-for-early-stage-hodgkin-s-lymphoma 2025-06-20T10:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/altum-sequencing-s-liquid-biopsy-technology-detects-breast-cancer-relapse-up-to-68-months-before-clinical-symptoms 2025-06-20T08:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/xjtlu-scientists-develop-ultra-stable-nanoparticles-with-40-drug-loading-capacity-for-enhanced-cancer-treatment 2025-06-20T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/bmj-investigation-uncovers-data-integrity-issues-in-astrazeneca-s-ticagrelor-heart-drug-trials 2025-06-20T05:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/hkbu-researchers-engineer-exosomes-to-deliver-alzheimer-s-drug-across-blood-brain-barrier 2025-06-20T04:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/cube-click-secures-fda-approval-for-smile-dx-ai-powered-dental-diagnostic-platform 2025-06-20T03:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/chemotherapy-free-regimens-and-car-t-therapies-transform-b-cell-malignancy-treatment-paradigms 2025-06-20T03:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/expert-panel-identifies-key-patient-factors-for-optimizing-immunotherapy-selection-in-pd-l1-negative-nsclc 2025-06-20T03:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-shows-consistent-efficacy-in-cervical-cancer-regardless-of-pd-l1-status-beatcc-trial-analysis-reveals 2025-06-20T02:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-secures-2-billion-option-deal-for-gilgamesh-s-next-generation-psychedelic-therapies 2025-06-20T01:40:54+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-wisconsin-researchers-develop-personalized-cancer-vaccines-using-pyroptotic-vesicles-to-prevent-tumor-recurrence 2025-06-20T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-treatment-for-atopic-dermatitis-linked-to-increased-psoriasis-risk-in-large-scale-study 2025-06-20T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-fibrinogen-concentrate-bt524-demonstrates-non-inferiority-in-phase-iii-trial-for-surgical-bleeding 2025-06-20T00:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/dgenthera-and-nusano-partner-to-scale-astatine-211-production-for-next-generation-cancer-therapy 2025-06-20T00:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/historical-challenges-in-nf1-associated-plexiform-neurofibroma-treatment-drive-development-of-targeted-therapies 2025-06-20T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/dendritic-cell-therapy-shows-significant-survival-benefit-for-recurrent-glioblastoma-patients 2025-06-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-cuts-63-of-workforce-as-company-restructures-operations-amid-pipeline-milestones 2025-06-19T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/cd5-targeted-therapies-show-promise-across-cancer-autoimmunity-and-transplantation-with-first-commercial-launch-expected-by-2030 2025-06-19T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-iii-essential-thrombocythemia-trial 2025-06-19T21:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/zilia-ocular-receives-world-first-health-canada-approval-for-non-invasive-retinal-oxygen-measurement 2025-06-19T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/cns-oligonucleotide-licensing-deals-surge-339-to-2-81-billion-in-2024 2025-06-19T20:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/beta-bionics-partners-with-abbott-to-integrate-ilet-bionic-pancreas-with-future-dual-glucose-ketone-sensor 2025-06-19T18:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-immunoglobulin-with-hyaluronidase-shows-promise-for-idiopathic-inflammatory-myositis-treatment 2025-06-19T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/theranica-s-nerivio-ren-wearable-shows-sustained-migraine-efficacy-over-three-years-in-real-world-studies 2025-06-19T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/tocilizumab-biosimilar-ct-p47-demonstrates-long-term-efficacy-and-safety-in-rheumatoid-arthritis-treatment 2025-06-19T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-alkaptonuria-nitisinone-shows-clinical-benefits-in-rare-metabolic-disorder 2025-06-19T17:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/excellthera-s-zemcelpro-receives-positive-chmp-opinion-for-blood-cancer-patients-without-suitable-donors 2025-06-19T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-analytics-summits-address-critical-quality-control-challenges-amid-regulatory-setbacks 2025-06-19T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-increased-risk-of-gallbladder-disease-in-large-scale-safety-analysis 2025-06-19T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/brenus-pharma-and-insphero-develop-advanced-3d-tumor-models-for-colorectal-cancer-immunotherapy-testing 2025-06-19T15:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/bionova-scientific-expands-into-advanced-therapies-with-third-flexfactory-platform-installation 2025-06-19T15:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-bmf-650-demonstrates-significant-weight-loss-in-primate-study-advancing-toward-clinical-trials 2025-06-19T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/pleopharma-s-pp-01-shows-significant-efficacy-in-phase-2b-trial-for-cannabis-withdrawal-syndrome 2025-06-19T13:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-pharmacopeia-recognizes-mass-photometry-as-key-method-for-aav-gene-therapy-quality-standards 2025-06-19T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/kras-g12c-nsclc-patients-face-limited-cns-treatment-options-despite-40-brain-metastases-rate 2025-06-19T13:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-to-present-phase-ii-results-for-first-in-class-bk-polyomavirus-treatment-at-world-transplant-congress 2025-06-19T12:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/doe-supplies-accelerator-produced-actinium-225-for-first-ever-u-s-cancer-therapy-clinical-trial 2025-06-19T11:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/synfini-and-o2nix-bio-partner-to-develop-ai-driven-cancer-metastasis-therapies-targeting-ftsj1 2025-06-19T09:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cancels-advisory-committee-meeting-for-capricor-s-duchenne-therapy-amid-leadership-shake-up 2025-06-19T09:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/medhub-ai-receives-pmda-approval-for-ai-powered-coronary-assessment-technology-in-japan 2025-06-19T09:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/tgs-and-viridien-launch-laconia-phase-iii-ocean-bottom-node-survey-in-gulf-of-america 2025-06-19T08:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/hotspot-therapeutics-to-present-irf5-small-molecule-inhibitor-data-at-focis-2025 2025-06-19T07:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-zaiming-initiates-us-phase-1-trial-of-trispecific-antibody-sim0500-for-relapsed-refractory-multiple-myeloma 2025-06-19T05:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/saptalis-pharmaceuticals-launches-fluoxetine-oral-solution-for-multiple-mental-health-conditions 2025-06-19T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-oncology-pharmacists-emerge-as-critical-players-in-personalized-cancer-care 2025-06-19T03:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/insulet-presents-real-world-evidence-of-omnipod-5-benefits-in-type-2-diabetes-at-ada-2025 2025-06-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-shuts-down-maryland-cell-therapy-manufacturing-following-car-t-trial-failure 2025-06-19T01:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-critical-safety-warning-for-scopolamine-patch-following-13-global-hyperthermia-cases 2025-06-19T01:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/kindeva-partners-with-rocket-science-health-to-advance-novel-intranasal-cns-drug-delivery-platform 2025-06-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-halts-clinical-trials-sending-american-cells-to-foreign-labs-for-genetic-engineering 2025-06-19T00:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-reveals-46-cognitive-decline-reduction-in-alzheimer-s-trial-reanalysis 2025-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genecentric-secures-8m-series-c-to-commercialize-rna-based-liquid-biopsy-platform 2025-06-18T22:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/avalo-therapeutics-appoints-rita-jain-to-board-as-avtx-009-phase-2-trial-for-hidradenitis-suppurativa-progresses 2025-06-18T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/kaiser-permanente-launches-fda-approved-gene-therapy-program-for-pediatric-sickle-cell-disease 2025-06-18T21:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tafasitamab-triple-combination-for-relapsed-refractory-follicular-lymphoma 2025-06-18T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/eccogene-initiates-phase-1b-trial-of-novel-oral-glp-1-receptor-agonist-azd5004-ecc5004-in-china 2025-06-18T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/dapagliflozin-combination-therapy-shows-promise-for-adolescents-with-type-1-diabetes-in-clinical-trial 2025-06-18T20:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-expands-tecnis-odyssey-iol-to-europe-middle-east-and-canada-following-us-success 2025-06-18T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/camurus-cam2029-shows-significant-liver-volume-reduction-in-phase-2b-trial-for-rare-polycystic-liver-disease 2025-06-18T20:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/tolremo-therapeutics-strengthens-leadership-with-key-appointments-as-tt125-802-shows-clinical-promise 2025-06-18T19:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/brightspring-s-onco360-pharmacy-selected-as-national-partner-for-three-new-cancer-and-rare-disease-therapies 2025-06-18T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-qulipta-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-head-to-head-migraine-prevention-trial 2025-06-18T18:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/singlera-genomics-gutseer-assay-achieves-81-5-sensitivity-in-detecting-early-stage-gastrointestinal-cancers 2025-06-18T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-partners-with-msd-to-expand-distribution-of-diabetes-drug-portfolio-in-india 2025-06-18T16:58:10+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-appoints-randall-kaye-as-chief-medical-advisor-following-positive-spinal-cord-injury-trial-results 2025-06-18T16:57:38+00:00 hourly 0.9 https://trial.medpath.com/news/curasight-advances-utreat-brain-cancer-therapy-with-phase-1-trial-submission-to-ema 2025-06-18T16:55:57+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-secures-india-patent-for-novel-spliceosome-inhibiting-adc-payload-technology 2025-06-18T16:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/respiratorius-secures-fda-pre-ind-meeting-for-val001-cancer-treatment-following-positive-physician-survey 2025-06-18T16:55:44+00:00 hourly 0.9 https://trial.medpath.com/news/infinity-bio-secures-8m-series-a-to-advance-antibody-reactome-profiling-technology 2025-06-18T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-strengthens-leadership-team-with-key-executive-appointments-to-advance-immune-mediated-disease-pipeline 2025-06-18T16:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/pattern-computer-advances-ai-discovered-drug-for-multiple-hard-to-treat-cancers-to-testing-phase 2025-06-18T16:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/fareva-opens-new-gmp-sterile-pilot-unit-in-france-to-support-biotech-drug-manufacturing 2025-06-18T16:46:20+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-releases-5-2-million-synthetic-molecules-dataset-to-accelerate-ai-driven-drug-discovery 2025-06-18T16:46:08+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-approves-over-the-counter-melatonin-and-prescription-psilocybin-for-treatment-resistant-depression 2025-06-18T16:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-sells-priority-review-voucher-for-160-million-following-chikungunya-vaccine-approval 2025-06-18T16:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-second-patient-treatment-in-australia 2025-06-18T16:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/diagonal-therapeutics-diag723-shows-disease-modifying-potential-for-hereditary-hemorrhagic-telangiectasia-in-preclinical-studies 2025-06-18T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-pediatric-trial-for-moleculin-s-annamycin-in-acute-myeloid-leukemia 2025-06-18T16:41:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-integrated-sacral-neuromodulation-system-for-urinary-urge-incontinence 2025-06-18T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-expanded-dosing-and-pediatric-indication-for-firdapse-in-lambert-eaton-myasthenic-syndrome 2025-06-18T16:41:04+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-study-identifies-three-b-cell-lymphoma-subgroups-with-distinct-cd19-car-t-response-patterns 2025-06-18T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/regeltec-initiates-u-s-pivotal-trial-for-hydrafil-system-in-chronic-low-back-pain-treatment 2025-06-18T16:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-launches-phase-3-pediatric-trial-of-omaveloxolone-for-friedreich-ataxia 2025-06-18T15:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-s-apitegromab-preserves-lean-muscle-mass-during-weight-loss-with-tirzepatide-in-phase-2-trial 2025-06-18T12:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/actio-biosciences-raises-66m-series-b-to-advance-rare-disease-programs-targeting-ion-channel-disorders 2025-06-18T12:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-strengthens-cmc-leadership-with-industry-veteran-ahead-of-phase-2-trial 2025-06-18T12:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-atogepant-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-phase-3-migraine-prevention-trial 2025-06-18T12:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/draig-therapeutics-emerges-from-stealth-with-140m-to-advance-novel-neuropsychiatric-therapies 2025-06-18T12:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-partners-with-phnyx-lab-to-deploy-ai-powered-drug-development-platform 2025-06-18T11:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/senate-republicans-drop-orphan-drug-exemptions-from-trump-tax-bill-dealing-blow-to-rare-disease-drug-development 2025-06-18T09:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-tzield-debuts-in-china-as-first-fda-approved-therapy-to-delay-type-1-diabetes-onset 2025-06-18T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/inoviq-s-car-exosome-therapy-achieves-88-cancer-cell-kill-rate-in-preclinical-study 2025-06-18T09:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/mercalis-and-pharmacord-merge-to-form-valeris-creating-integrated-therapy-commercialization-platform 2025-06-18T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-msn-settle-entresto-patent-dispute-boosting-divi-s-laboratories-outlook 2025-06-18T09:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-simultaneous-whole-exome-and-transcriptome-cancer-test-for-precision-oncology 2025-06-18T09:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/nec-and-chugai-pharmaceutical-develop-ai-system-to-accelerate-cancer-drug-combination-discovery 2025-06-18T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/expanding-innovations-receives-fda-clearance-for-n-gage-lumbar-plate-system 2025-06-18T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-announces-leadership-transition-as-ceo-dr-james-hayward-retires-after-20-year-tenure 2025-06-18T06:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharma-receives-five-fda-observations-at-north-carolina-facility-no-data-integrity-issues-found 2025-06-18T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/saverone-receives-us-patent-for-advanced-sensor-fusion-technology-to-combat-driver-distraction 2025-06-18T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/blue-biofuels-secures-seventh-u-s-patent-for-cellulose-to-sugar-technology 2025-06-18T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/medibank-partners-with-emyria-to-fund-innovative-ptsd-treatment-program-in-australian-healthcare-first 2025-06-18T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/occam-immune-and-cancer-research-institute-form-strategic-partnership-to-advance-personalized-immunotherapy 2025-06-18T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-stedim-biotech-completes-major-manufacturing-expansion-in-france-to-meet-growing-bioprocessing-demand 2025-06-18T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-strengthens-ndv-01-bladder-cancer-program-with-key-leadership-appointments-ahead-of-phase-3-trial 2025-06-18T02:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-and-scibase-partner-to-develop-ai-powered-atopic-dermatitis-flare-prediction-test 2025-06-18T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/medtech-products-recalls-little-remedies-honey-cough-syrup-nationwide-due-to-bacterial-contamination 2025-06-18T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-receives-23-7-million-arpa-h-grant-to-map-immunotherapy-resistance-in-lung-cancer 2025-06-18T00:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-healthcare-forms-joint-venture-with-mind-medicine-australia-to-launch-psychedelic-therapy-clinic-in-melbourne 2025-06-18T00:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/nmdp-access-trial-shows-mismatched-donors-expand-stem-cell-transplant-access-for-blood-cancer-patients 2025-06-18T00:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-research-foundation-and-boehringer-ingelheim-launch-2-25-million-initiative-to-target-her2-mutant-lung-cancer 2025-06-18T00:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/microbot-medical-secures-china-patent-for-liberty-robotic-system-ahead-of-q3-2025-us-launch 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/three-minute-eeg-test-shows-promise-for-early-alzheimer-s-detection-in-clinical-trial 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mitochondrial-biomarkers-identified-for-atrial-fibrillation-through-integrated-bioinformatics-analysis 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tislelizumab-shows-promise-as-adjuvant-therapy-for-high-risk-hepatocellular-carcinoma-patients 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-cfo-resigns-amid-amtagvi-launch-struggles-and-securities-fraud-investigation 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/earlyhealth-group-acquires-turkish-pharmaceutical-distributor-corena-in-100m-life-sciences-expansion 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-georgia-develops-first-broad-spectrum-fungal-vaccine-enters-clinical-trials 2025-06-17T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/canada-outpaces-oecd-countries-in-new-medicine-launches-despite-rising-treatment-costs 2025-06-17T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/bioaegis-therapeutics-receives-fda-fast-track-designation-for-novel-ards-treatment 2025-06-17T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/exceptional-responders-14-pancreatic-cancer-patients-show-remarkable-immunotherapy-outcomes-in-multi-institutional-study 2025-06-17T21:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/celltrio-secures-15-million-to-accelerate-global-expansion-of-cell-therapy-automation-platform 2025-06-17T21:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-labs-partners-with-norwegian-biobank-to-accelerate-aging-related-drug-discovery 2025-06-17T21:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/skyhawk-therapeutics-initiates-phase-2-3-trial-of-sky-0515-for-huntington-s-disease 2025-06-17T20:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/ashvattha-therapeutics-unveils-novel-nanomedicine-radiotracers-for-neuroinflammation-and-cancer-imaging-at-snmmi-2025 2025-06-17T20:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/visby-medical-secures-65-million-to-launch-fda-authorized-at-home-sti-test 2025-06-17T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/pelage-pharmaceuticals-pp405-shows-hair-regeneration-potential-in-phase-2a-trial 2025-06-17T20:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-launches-in-florida-to-test-investigational-oral-medication-for-severe-thunderstorm-aversion-in-dogs 2025-06-17T19:11:09+00:00 hourly 0.9 https://trial.medpath.com/news/quilt-health-secures-6m-seed-funding-to-modernize-clinical-trial-access-for-complex-diseases 2025-06-17T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/nature-study-validates-non-invasive-fat-reduction-technology-for-abdominal-obesity-treatment 2025-06-17T18:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/maxion-therapeutics-strengthens-leadership-with-appointment-of-dr-stefan-hartle-as-chief-development-officer 2025-06-17T18:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/heart-drug-cilostazol-shows-promise-for-treating-growth-disorders-in-preclinical-study 2025-06-17T18:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-cost-plus-drug-company-expands-affordable-healthcare-access-through-strategic-partnerships 2025-06-17T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulator-reports-111-deaths-potentially-linked-to-glp-1-weight-loss-medications 2025-06-17T16:56:27+00:00 hourly 0.9 https://trial.medpath.com/news/avata-biosciences-secures-95m-partnership-with-oceanus-bio-for-novel-cbd-therapies-in-asian-markets 2025-06-17T16:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/aragen-to-launch-gmp-biologics-manufacturing-in-india-with-advanced-fed-batch-platform 2025-06-17T16:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/llusern-scientific-achieves-iso-13485-certification-for-rapid-uti-diagnostic-system 2025-06-17T16:55:24+00:00 hourly 0.9 https://trial.medpath.com/news/sunrock-biopharma-and-escugen-partner-to-develop-first-in-class-ccr9-targeted-adc-for-solid-tumors 2025-06-17T16:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-partners-with-noetik-to-develop-ai-powered-biomarkers-for-precision-immunotherapy 2025-06-17T16:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-s-hcb101-checkpoint-inhibitor-shows-promising-safety-and-efficacy-balance-in-phase-1b-trial 2025-06-17T16:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-secures-452-5m-licensing-deal-for-gastroparesis-drug-pcs12852 2025-06-17T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-medicovestor-s-first-in-class-adc-for-pancreatic-cancer 2025-06-17T16:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/astrocyte-pharmaceuticals-initiates-phase-2-trial-for-first-in-class-concussion-drug-ast-004 2025-06-17T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-appoints-new-ceo-and-board-members-to-advance-opioid-antagonist-th104-development 2025-06-17T16:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/lipella-pharmaceuticals-secures-patent-for-mri-based-diagnostic-technology-to-detect-interstitial-cystitis 2025-06-17T16:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-proposes-elimination-of-phase-iii-clinical-trials-for-biosimilar-approvals 2025-06-17T16:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/phoenix-study-launches-world-s-largest-pharmacogenomics-trial-to-personalize-drug-prescribing-in-scotland 2025-06-17T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-s-jyong-biotech-raises-20m-in-nasdaq-ipo-to-advance-botanical-urinary-disease-treatments 2025-06-17T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/china-proposes-30-day-review-pathway-for-innovative-drug-clinical-trials-nationwide 2025-06-17T14:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-expands-precision-guided-dosing-platform-with-new-tests-for-ibd-biologics 2025-06-17T14:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-completes-enrollment-in-phase-3-trial-for-central-precocious-puberty-treatment 2025-06-17T13:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/tisento-therapeutics-receives-fda-fast-track-designation-for-zagociguat-in-melas-treatment 2025-06-17T13:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/qureight-s-ai-powered-synthetic-control-arms-validate-efficacy-of-avalyn-s-inhaled-pirfenidone-for-rare-lung-disease 2025-06-17T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-launches-eur50-million-corporate-bond-to-accelerate-biosimilar-portfolio-development 2025-06-17T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/basf-opens-new-gmp-solution-center-in-michigan-to-strengthen-biopharma-manufacturing-capabilities 2025-06-17T13:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/isomorphic-labs-appoints-dr-ben-wolf-as-chief-medical-officer-establishes-us-operations 2025-06-17T12:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-researchers-develop-car-t-therapy-for-aggressive-bladder-cancer-variant-using-novel-biomarkers 2025-06-17T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-and-parkinson-s-charities-launch-drug-repurposing-partnership-to-accelerate-treatment-development 2025-06-17T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/vsa-announces-acquisition-of-ai-clinical-development-company-hopeai-to-transform-drug-development-timelines 2025-06-17T12:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/nodthera-appoints-former-astrazeneca-executive-elisabeth-bjork-to-board-as-phase-2-obesity-trial-advances 2025-06-17T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-gene-editing-biotech-verve-therapeutics-for-1-3-billion-to-expand-cholesterol-treatment-pipeline 2025-06-17T10:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/china-patent-office-upholds-harbour-biomed-s-heavy-chain-antibody-patent-in-legal-victory-over-biocytogen 2025-06-17T10:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/angle-advances-liquid-biopsy-technology-with-dual-dna-analysis-and-androgen-receptor-profiling-at-eacr-2025 2025-06-17T10:58:21+00:00 hourly 0.9 https://trial.medpath.com/news/orion-and-glykos-extend-adc-partnership-to-develop-six-next-generation-cancer-therapies 2025-06-17T09:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/simvastatin-fails-to-show-antidepressant-benefits-in-major-depression-and-obesity-trial 2025-06-17T09:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-proposes-streamlined-30-day-review-channel-for-category-1-innovative-drugs 2025-06-17T09:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/hera-biotech-acquires-herafem-point-of-care-cervical-cancer-diagnostic-with-91-sensitivity 2025-06-17T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/smartlabs-and-iwg-form-10-year-partnership-to-expand-global-lab-infrastructure-access 2025-06-17T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/everzom-secures-eur3-million-france-2030-funding-to-scale-exosome-bioproduction-for-crohn-s-disease-treatment 2025-06-17T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-submits-fda-application-for-next-generation-lungfit-ph-ii-nitric-oxide-system 2025-06-17T05:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-secures-major-manufacturing-deal-to-scale-cu-sar-bispsma-production-for-prostate-cancer-diagnostics 2025-06-17T05:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/biomx-achieves-breakthrough-in-phage-therapy-with-positive-phase-2-results-for-antibiotic-resistant-infections 2025-06-17T05:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-abbott-s-rapid-whole-blood-test-for-concussion-assessment 2025-06-17T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-activity-plummets-20-as-funding-crisis-grips-biotech-sector 2025-06-17T03:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/thyroid-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-06-17T02:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-secures-7-4-billion-opioid-settlement-support-from-55-states-and-territories 2025-06-17T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-csl-s-andembry-for-hereditary-angioedema-prevention-with-novel-factor-xiia-targeting 2025-06-17T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-leqembi-shows-accelerating-growth-with-58-global-sales-increase-despite-slow-market-adoption 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/trust-trial-shows-primary-surgery-improves-progression-free-survival-in-advanced-ovarian-cancer-despite-missing-overall-survival-endpoint 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-second-complete-response-letter-for-odronextamab-in-relapsed-refractory-follicular-lymphoma 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/digital-inhaler-technology-shows-promise-for-early-copd-exacerbation-detection 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-detects-early-liver-transplant-rejection-using-cell-free-dna-analysis 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/mabion-and-novalgen-partner-to-advance-novel-t-cell-engager-nvg-222-for-cancer-treatment 2025-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enzene-expands-new-jersey-biomanufacturing-facility-by-26000-square-feet-ahead-of-opening 2025-06-16T23:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/edx-medical-partners-with-spire-healthcare-to-advance-diagnostic-innovation-for-cancer-and-cardiovascular-disease 2025-06-16T23:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/help-therapeutics-partners-with-china-resources-sanjiu-to-advance-ipsc-derived-heart-failure-therapy-hicm-188 2025-06-16T23:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/cresilon-expands-vetigel-distribution-to-canadian-veterinary-market-through-mccarthy-vet-partnership 2025-06-16T22:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-reports-complete-response-in-advanced-nsclc-patient-after-failed-standard-therapies 2025-06-16T22:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/shasqi-achieves-first-in-human-success-with-click-chemistry-cancer-therapy-delivering-12-fold-higher-doxorubicin-doses 2025-06-16T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-receives-ema-approval-to-skip-phase-1-2-trials-for-mpox-vaccine-accelerating-path-to-market 2025-06-16T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-surovatamig-shows-promise-as-next-generation-bite-therapy-for-relapsed-refractory-b-all 2025-06-16T21:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/patent-extensions-drive-200-billion-in-excess-u-s-drug-spending-i-mak-analysis-reveals 2025-06-16T21:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/clarametyx-s-cmtx-101-shows-promise-in-cystic-fibrosis-infection-trial-advances-to-next-phase 2025-06-16T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/eolo-pharma-s-sana-demonstrates-novel-energy-burning-mechanism-for-obesity-treatment-in-first-in-human-study 2025-06-16T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-cdmo-cro-services-can-reduce-drug-development-timelines-by-nearly-three-years-tufts-study-finds 2025-06-16T21:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/asc2escalate-trial-shows-promising-results-for-asciminib-in-second-line-cml-treatment 2025-06-16T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-mrna-cancer-vaccine-shows-promise-in-groundbreaking-bowel-cancer-trial 2025-06-16T19:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-pharmaceuticals-acquires-sage-therapeutics-for-795-million-strengthening-neuropsychiatry-portfolio 2025-06-16T18:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/solu-therapeutics-appoints-enda-moran-as-coo-to-scale-cytac-platform-operations 2025-06-16T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-pharmaceuticals-acquires-sage-therapeutics-for-up-to-795-million-securing-postpartum-depression-drug-zurzuvae 2025-06-16T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/liso-cel-achieves-95-5-response-rate-in-relapsed-refractory-marginal-zone-lymphoma 2025-06-16T17:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/single-psilocybin-dose-provides-two-year-depression-relief-in-cancer-patients 2025-06-16T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/virogates-and-genspeed-achieve-breakthrough-in-point-of-care-chronic-inflammation-testing-for-longevity-market 2025-06-16T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-submits-ind-application-for-once-monthly-obesity-drug-mbx-4291 2025-06-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-loses-canadian-semaglutide-patent-protection-over-missed-450-fee-opening-door-to-generics-in-2026 2025-06-16T17:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/bdd-pharma-s-oralogik-system-advances-timed-release-drug-delivery-for-adhd-and-rheumatoid-arthritis 2025-06-16T17:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-treated-with-novel-b-cell-targeting-therapy-for-myasthenia-gravis-in-phase-iii-trial 2025-06-16T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/alzamend-neuro-completes-5-million-financing-to-advance-five-phase-ii-trials-for-al001-lithium-therapy 2025-06-16T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/zircon-phase-3-trial-demonstrates-high-accuracy-of-novel-pet-tracer-for-kidney-cancer-detection 2025-06-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-sponsors-first-clinical-trial-of-needle-free-rotavirus-vaccine-using-dissolvable-microarray-patch-technology 2025-06-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-fosun-pharma-form-strategic-partnership-for-novel-anti-pd1-il2-cancer-immunotherapy-tev-56278 2025-06-16T16:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-initiates-first-in-human-trial-of-cd37-targeted-adc-debio-1562m-for-relapsed-refractory-aml 2025-06-16T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-verona-trial-for-high-risk-myelodysplastic-syndrome-fails-to-meet-primary-survival-endpoint 2025-06-16T16:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/penumbra-completes-enrollment-in-landmark-storm-pe-trial-testing-thrombectomy-for-pulmonary-embolism 2025-06-16T16:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-molecules-completes-phase-1b-enrollment-for-novel-hsv-inhibitor-im-250 2025-06-16T16:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/xlife-sciences-expands-asian-footprint-through-strategic-partnerships-in-digital-health-and-precision-oncology 2025-06-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-s-nuz-001-demonstrates-neuroprotective-effects-in-huntington-s-disease-zebrafish-model 2025-06-16T15:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/ubrigene-launches-gmp-compliant-ipsc-banks-to-accelerate-cell-therapy-development 2025-06-16T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/quiver-bioscience-names-co-founder-graham-dempsey-ceo-to-advance-nav1-7-targeting-aso-for-chronic-pain 2025-06-16T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/elite-pharmaceuticals-achieves-bioequivalence-for-generic-anticoagulant-in-27-billion-market 2025-06-16T12:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/d-d-pharmatech-s-dd01-shows-rapid-liver-fat-reduction-in-mash-phase-2-trial-matching-competitor-results-in-quarter-of-the-time 2025-06-16T12:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-s-cid-078-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment 2025-06-16T12:51:26+00:00 hourly 0.9 https://trial.medpath.com/news/nextcure-and-simcere-zaiming-form-strategic-partnership-for-cdh6-targeting-adc-sim0505 2025-06-16T12:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-inca033989-shows-86-response-rate-in-calr-mutant-blood-cancer-trial 2025-06-16T12:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/pierre-fabre-acquires-global-rights-to-next-generation-egfr-inhibitors-for-nsclc-treatment 2025-06-16T12:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-blood-test-enables-celiac-disease-diagnosis-without-gluten-challenge 2025-06-16T12:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/bluegenes-and-levrx-partner-to-integrate-real-time-pharmacogenetic-testing-into-pharmacy-benefit-systems 2025-06-16T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-partners-with-university-of-alberta-to-advance-pnkp-inhibitor-research-for-glioblastoma-treatment 2025-06-16T08:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/varenicline-bupropion-combination-shows-promise-for-alcohol-use-disorder-treatment 2025-06-16T08:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/s-biomedics-reports-promising-12-month-data-for-parkinson-s-cell-therapy-a9-dpc-in-phase-1-2a-trial 2025-06-16T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/tg01-cancer-vaccine-shows-promising-clinical-activity-in-ras-mutant-multiple-myeloma 2025-06-16T08:47:36+00:00 hourly 0.9 https://trial.medpath.com/news/pulmovant-publishes-phase-1-data-supporting-once-daily-inhaled-mosliciguat-for-pulmonary-hypertension 2025-06-16T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/klotho-neurosciences-raises-11-million-through-warrant-exercises-achieves-debt-free-status 2025-06-16T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/poltreg-establishes-u-s-subsidiary-immuthera-and-receives-positive-ema-opinion-for-type-1-diabetes-cell-therapy 2025-06-16T06:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/olverembatinib-shows-promising-results-in-multiple-philadelphia-chromosome-positive-all-studies 2025-06-16T05:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/uk-flair-trial-demonstrates-superior-outcomes-with-chemotherapy-free-combination-therapy-for-chronic-lymphocytic-leukaemia 2025-06-16T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/adolore-biotherapeutics-reports-positive-preclinical-data-for-gene-therapy-targeting-chronic-knee-pain 2025-06-16T00:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-expands-into-preclinical-research-with-launch-of-samsung-organoids-drug-screening-platform 2025-06-16T00:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-app-to-feature-clinical-trial-matching-system-as-uk-targets-150-day-setup-times 2025-06-16T00:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-and-kailera-present-phase-2-data-for-dual-glp-1-gip-agonist-and-oral-glp-1-therapies-at-ada-2025 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/axcelead-and-a2-healthcare-form-strategic-partnership-to-accelerate-drug-r-d-in-japan 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-formally-rescinds-laboratory-developed-test-rule-following-court-defeat 2025-06-15T21:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-degrader-bgb-16673-achieves-84-8-response-rate-in-heavily-pretreated-cll-sll-patients 2025-06-15T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-s-crispr-gene-therapy-shows-98-reduction-in-hae-attacks-after-three-years 2025-06-15T16:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/adalimumab-biosimilars-show-high-acceptance-and-long-term-durability-in-ibd-patients-across-age-groups 2025-06-15T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/socioeconomic-disparities-drive-worse-outcomes-in-multiple-myeloma-patients-despite-treatment-advances 2025-06-15T03:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/eha-2025-showcases-breakthrough-therapies-for-hematologic-malignancies 2025-06-15T03:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/biologic-therapies-transform-respiratory-care-as-clinicians-embrace-earlier-precision-based-treatment-strategies 2025-06-15T03:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/sigachi-industries-secures-environmental-approval-for-major-api-manufacturing-facility-in-andhra-pradesh 2025-06-15T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/syngene-international-s-bengaluru-facility-receives-clean-fda-inspection-with-nai-status 2025-06-15T01:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/twin-health-raises-53-million-to-scale-ai-powered-digital-twin-platform-for-metabolic-disease-management 2025-06-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ethniq-launches-patented-natural-antifungal-treatment-showing-90-efficacy-in-clinical-trials 2025-06-14T23:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-names-kirti-ganorkar-as-managing-director-in-major-leadership-transition 2025-06-14T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/multimodal-ai-system-demonstrates-superior-survival-prediction-for-hepatocellular-carcinoma-immunotherapy 2025-06-14T21:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/nice-rejects-first-alzheimer-s-disease-modifying-drugs-for-nhs-use-due-to-cost-effectiveness-concerns 2025-06-14T20:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/natco-pharma-s-mekaguda-api-facility-receives-fda-establishment-inspection-report-following-successful-remediation 2025-06-14T20:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/inspiremd-receives-fda-approval-for-cguard-prime-carotid-stent-system-with-record-low-stroke-rates 2025-06-14T18:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapies-show-promise-for-severe-autoimmune-diseases-at-eular-2025 2025-06-14T17:00:42+00:00 hourly 0.9 https://trial.medpath.com/news/benchling-partners-with-merck-to-streamline-vaccine-bioanalysis-through-integrated-digital-platform 2025-06-14T16:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-advances-targeted-protein-degradation-platform-with-new-clinical-data-at-eha-2025 2025-06-14T12:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-halol-facility-receives-eight-fda-observations-following-latest-inspection 2025-06-14T10:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/itm-to-present-phase-3-compete-trial-data-at-snmmi-2025-meeting 2025-06-14T05:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/regor-therapeutics-to-present-phase-2a-data-for-oral-glp-1-agonist-rgt-075-at-ada-2025 2025-06-14T04:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/food-deserts-compound-clinical-trial-access-barriers-for-breast-cancer-patients 2025-06-14T03:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-kalvista-s-sebetralstat-approval-decision-due-to-resource-constraints 2025-06-14T02:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/intravenous-rehydration-shows-safety-in-severely-malnourished-children-challenging-who-guidelines 2025-06-14T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-sebetralstat-approval-decision-for-hereditary-angioedema-treatment-due-to-resource-constraints 2025-06-14T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/olutasidenib-maintenance-therapy-demonstrates-sustained-remission-in-idh1-mutated-aml-patients 2025-06-13T23:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-explores-4-billion-diagnostics-unit-sale-to-streamline-portfolio 2025-06-13T22:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/neuroem-therapeutics-secures-1-33-million-in-series-a-funding-to-advance-drug-free-alzheimer-s-treatment 2025-06-13T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/ponatinib-shows-superior-survival-outcomes-in-ph-all-patients-with-persistent-mrd-after-induction 2025-06-13T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/nectero-medical-secures-cpt-codes-for-investigational-aaa-treatment-as-phase-2-3-trial-shows-promise 2025-06-13T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/cyclophosphamide-plus-cyclosporin-emerges-as-new-standard-of-care-for-gvhd-prevention-in-blood-cancer-transplants 2025-06-13T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-advances-liposomal-cbd-platform-for-chronic-pain-as-peer-reviewed-study-highlights-non-opioid-alternative 2025-06-13T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-first-eu-vaccine-against-swine-dysentery-targeting-disease-with-30-50-mortality-rate 2025-06-13T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-launches-combine-pilot-program-to-streamline-combined-medicine-and-medical-device-studies 2025-06-13T20:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-cbp-p300-inhibitor-tt125-802-shows-promise-in-treatment-resistant-nsclc 2025-06-13T19:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/ellipsis-health-raises-45m-series-a-to-launch-sage-ai-care-manager-with-emotional-intelligence 2025-06-13T19:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/serum-institute-of-india-partners-with-dndi-to-develop-affordable-dengue-monoclonal-antibody-treatment 2025-06-13T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/fapi-based-pet-imaging-shows-superior-performance-over-fdg-pet-for-gastrointestinal-cancer-detection 2025-06-13T17:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccination-reduces-severe-kidney-damage-risk-in-hospitalized-patients-ucla-study-finds 2025-06-13T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-dual-targeting-car-t-therapy-achieves-80-complete-response-rate-in-lymphoma-trial 2025-06-13T17:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/nextcell-pharma-completes-patient-dosing-in-phase-ii-protrans-young-trial-for-pediatric-type-1-diabetes 2025-06-13T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/vial-doses-first-participants-in-phase-1-trial-of-half-life-extended-anti-tl1a-antibody-for-ibd-treatment 2025-06-13T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/panavance-therapeutics-reports-promising-phase-1-results-for-misetionamide-in-pancreatic-cancer 2025-06-13T17:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-announces-5-billion-u-s-biologics-manufacturing-investment-to-strengthen-supply-chain 2025-06-13T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/pegloticase-achieves-complete-gout-remission-in-43-of-patients-after-52-weeks-of-treatment 2025-06-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-rocket-pharmaceuticals-gene-therapy-trial-after-patient-death 2025-06-13T16:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/citius-pharmaceuticals-closes-15-8m-direct-offering-to-fund-lymphir-commercial-launch 2025-06-13T15:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/quest-diagnostics-partners-with-md-anderson-to-develop-multi-cancer-risk-blood-test-for-2026-launch 2025-06-13T14:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-launches-nabota-botulinum-toxin-in-qatar-completing-gulf-market-expansion 2025-06-13T14:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/medera-showcases-human-mini-heart-technology-breakthroughs-at-isscr-2025-advancing-gene-therapy-clinical-trials 2025-06-13T13:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/who-s-mrna-technology-transfer-programme-enters-phase-2-0-targeting-commercial-scale-production-in-low-and-middle-income-countries 2025-06-13T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-testing-emerges-as-key-decision-tool-for-post-transplant-multiple-myeloma-management 2025-06-13T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcma-targeted-bispecific-antibody-cm336-shows-promise-for-refractory-autoimmune-hemolytic-anemia-in-nejm-study 2025-06-13T12:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/dry-eye-disease-affects-16-4-million-americans-as-new-targeted-therapies-enter-development-pipeline 2025-06-13T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiomedix-launches-raha-100-bench-top-generator-to-expand-lead-212-supply-for-targeted-alpha-therapy 2025-06-13T10:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-show-promise-for-idiopathic-pulmonary-fibrosis-and-progressive-pulmonary-fibrosis-treatment 2025-06-13T10:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-in-human-trial-for-novel-car-t-therapy-targeting-neuroblastoma 2025-06-13T08:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/large-real-world-study-finds-no-increased-cancer-or-cardiovascular-risk-with-jak-inhibitors-in-rheumatoid-arthritis 2025-06-13T08:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/mitsubishi-research-institute-and-astellas-partner-to-accelerate-japanese-drug-discovery-startups 2025-06-13T08:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/merry-life-advances-first-in-class-alzheimer-s-drug-tml-6-to-global-phase-ii-trial 2025-06-13T08:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-secures-up-to-22-million-to-advance-phase-3-ataxia-telangiectasia-trial 2025-06-13T08:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/viz-ai-receives-first-fda-clearance-for-ai-powered-subdural-hemorrhage-measurement-technology 2025-06-13T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/prolaris-genomic-test-advances-personalized-prostate-cancer-treatment-with-precision-therapy-selection 2025-06-13T05:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-to-present-phase-3-results-of-dual-glp-1-glucagon-receptor-agonist-mazdutide-at-ada-2025 2025-06-13T03:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/early-colorectal-cancer-screening-at-age-40-reduces-death-risk-by-39-taiwan-study-shows 2025-06-13T03:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-secures-french-regulatory-pathway-for-lumevoq-gene-therapy-in-rare-blindness-disease 2025-06-13T02:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-becomes-first-health-system-globally-to-approve-trojan-horse-cancer-therapy-for-multiple-myeloma 2025-06-13T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/iom-bioworks-secures-rs-4-crore-seed-funding-to-advance-ai-powered-gut-microbiome-healthcare-platform 2025-06-13T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/starton-therapeutics-launches-phase-2a-trial-for-continuous-low-dose-lenalidomide-in-multiple-myeloma 2025-06-13T01:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-launch-world-first-clinical-trial-of-pmr-116-to-target-undruggable-myc-driven-cancers 2025-06-13T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-s-zenrelia-receives-positive-eu-regulatory-opinion-for-canine-allergic-dermatitis-treatment 2025-06-13T01:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/merck-animal-health-receives-eu-regulatory-milestone-for-first-in-class-jak-inhibitor-numelvi-for-canine-allergic-dermatitis 2025-06-13T01:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-pain-market-poised-for-transformation-with-novel-non-opioid-therapies-by-2034 2025-06-13T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/tazemetostat-pinometostat-combination-shows-promise-for-b-cell-lymphoma-treatment-resistance 2025-06-13T00:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/silence-therapeutics-reports-promising-phase-1-data-for-divesiran-in-polycythemia-vera-at-eha-2025 2025-06-13T00:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-abbvie-s-venclexta-plus-gazyva-as-first-line-chemotherapy-free-treatment-for-cll 2025-06-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tekton-research-adds-fourth-clinical-site-in-2025-with-richmond-pediatric-associates-partnership 2025-06-12T23:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/ouro-medicines-initiates-phase-1b-trial-of-om336-in-autoimmune-cytopenias-following-fda-orphan-drug-designation 2025-06-12T23:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/courage-therapeutics-appoints-giovanni-ferrara-as-ceo-to-advance-melanocortin-targeted-obesity-treatments 2025-06-12T21:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-non-surgical-treatment-for-non-muscle-invasive-bladder-cancer 2025-06-12T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/major-us-pharmaceutical-wholesalers-expand-market-control-through-strategic-practice-management-acquisitions 2025-06-12T21:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/bbot-s-bbo-10203-shows-broad-anti-tumor-activity-in-science-publication-advances-to-phase-1-trial 2025-06-12T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/autonomize-ai-secures-28-million-series-a-to-scale-ai-driven-healthcare-operations-platform 2025-06-12T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-grants-orphan-drug-designation-to-florbetaben-18f-for-attr-amyloidosis-diagnosis 2025-06-12T21:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/parallel-bio-raises-21-million-series-a-to-revolutionize-drug-discovery-with-human-organoid-platform 2025-06-12T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/specialised-therapeutics-expands-incyte-partnership-to-bring-two-novel-cancer-therapies-to-asia-pacific 2025-06-12T20:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/apex-labs-expands-phase-2b-psilocybin-ptsd-trial-to-israel-with-ministry-of-health-approval 2025-06-12T20:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-bleximenib-shows-promising-results-in-phase-1b-aml-trial-with-82-response-rate 2025-06-12T18:01:36+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-invalidation-of-agilent-s-crispr-guide-rna-patents-in-synthego-victory 2025-06-12T18:00:38+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-immunotherapeutics-secures-1-38m-funding-as-cdmo-business-accelerates-toward-2m-revenue-target 2025-06-12T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-inc-negotiates-strategic-partnership-changes-with-german-parent-company 2025-06-12T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/alys-pharmaceuticals-advances-first-in-class-mast-cell-selective-c-kit-inhibitor-aly-301-to-clinical-trials-for-cold-urticaria 2025-06-12T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-secures-japanese-patent-for-novel-mast-cell-targeting-platform-ht-kit 2025-06-12T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/volition-s-nu-q-h3-1-biomarker-shows-promise-for-sepsis-assessment-in-large-icu-study 2025-06-12T17:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/cmv-treatment-pipeline-expands-with-20-therapies-from-leading-pharmaceutical-companies 2025-06-12T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/chlorhexidine-impregnated-central-venous-catheters-reduce-icu-bloodstream-infections-by-70-5-in-multinational-study 2025-06-12T17:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-s-vasceptor-receives-fda-orphan-drug-designation-for-sickle-cell-disease-treatment 2025-06-12T17:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/adc-therapeutics-secures-100-million-financing-to-advance-zynlonta-development-through-2028 2025-06-12T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-reports-breakthrough-preclinical-results-for-fshd-gene-therapy-dyne-302 2025-06-12T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/rebel-medicine-secures-6m-series-a-funding-and-fda-ind-clearance-for-non-opioid-pain-therapy-alevatrix 2025-06-12T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-partners-with-sygnature-discovery-to-expand-ai-driven-drug-discovery-platform-access 2025-06-12T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-develops-exclusive-3d-liver-toxicity-models-for-labcorp-to-accelerate-drug-discovery 2025-06-12T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/alzecure-receives-fda-support-for-acd440-development-in-rare-pain-disorder-erythromelalgia 2025-06-12T17:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-sumitomo-s-nuvisertib-for-myelofibrosis-treatment 2025-06-12T17:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/syensqo-opens-world-s-largest-microbiology-lab-in-france-to-accelerate-biodegradable-product-development 2025-06-12T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-secures-manufacturing-patent-for-ampligen-through-2041 2025-06-12T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/screenin3d-secures-ps750000-to-accelerate-cancer-drug-development-with-lab-on-a-chip-technology 2025-06-12T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-secures-fda-approval-for-generic-prednisolone-acetate-eye-drops-targeting-201-million-market 2025-06-12T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/nanoform-initiates-pivotal-bioequivalence-studies-for-nanoenzalutamide-prostate-cancer-treatment 2025-06-12T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-s-ai-designed-glp-1-peptides-outperform-semaglutide-in-receptor-activation-studies 2025-06-12T14:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/mina-therapeutics-reports-breakthrough-pre-clinical-results-for-rna-based-sickle-cell-disease-treatment 2025-06-12T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-reveals-943-autoimmune-collaboration-and-licensing-deals-across-30-diseases-from-2016-2025 2025-06-12T12:51:42+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-to-acquire-curevac-for-1-25-billion-to-strengthen-mrna-cancer-immunotherapy-pipeline 2025-06-12T12:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/sensible-biotechnologies-achieves-90-reduction-in-mrna-optimization-time-using-ai-powered-platform 2025-06-12T12:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-completes-1-6-billion-global-manufacturing-expansion-to-boost-biopharmaceutical-supply-chain 2025-06-12T12:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-researchers-develop-antibody-treatment-to-restore-vision-in-retinitis-pigmentosa 2025-06-12T12:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-phase-3-trial-for-single-dose-dengue-vaccine-v181-targeting-global-public-health-crisis 2025-06-12T12:46:36+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antimicrobial-strategies-show-promise-against-drug-resistant-pathogens 2025-06-12T10:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-secures-20-million-to-advance-phase-3-trial-of-udenafil-for-rare-congenital-heart-disease 2025-06-12T09:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/spikimm-secures-worldwide-license-for-anti-bk-virus-monoclonal-antibodies-to-protect-transplant-patients 2025-06-12T09:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/astrivax-therapeutics-appoints-former-bayer-pharma-ceo-dieter-weinand-as-board-chairman 2025-06-12T09:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-secures-19-million-to-advance-novel-oncomimics-immunotherapy-for-indolent-non-hodgkin-lymphoma 2025-06-12T09:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-reports-breakthrough-results-from-in-vivo-gene-therapy-ctx310-for-heart-disease 2025-06-12T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-reports-sustained-safety-profile-for-epysqli-biosimilar-in-long-term-pnh-study 2025-06-12T09:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/snipr-biome-doses-first-patient-with-crispr-armed-phage-therapy-snipr001-for-drug-resistant-e-coli-prevention 2025-06-12T09:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/cytovale-s-intellisep-diagnostic-reduces-sepsis-mortality-by-39-in-large-real-world-study 2025-06-12T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/mro-acquires-q-centrix-to-create-comprehensive-clinical-data-management-platform 2025-06-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/moleculight-fluorescence-imaging-demonstrates-superior-outcomes-in-deep-sternal-wound-infections-reducing-costs-and-complications 2025-06-12T06:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-spectris-ad-demonstrates-significant-delay-in-alzheimer-s-disease-progression-through-non-invasive-neuromodulation 2025-06-12T06:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/qlaris-bio-develops-novel-fixed-dose-combination-therapy-targeting-unaddressed-component-of-glaucoma-treatment 2025-06-12T06:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/juvena-therapeutics-partners-with-eli-lilly-in-ai-driven-muscle-health-drug-discovery-collaboration 2025-06-12T05:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/rutgers-study-challenges-fda-heart-safety-warning-for-epilepsy-drug-lamotrigine 2025-06-12T05:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-replaces-entire-cdc-vaccine-advisory-committee-with-eight-new-members 2025-06-12T03:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-oncology-drug-delivery-transforms-cancer-care-with-fda-approved-formulations 2025-06-12T03:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/toripalimab-emerges-as-preferred-pd-1-inhibitor-for-metastatic-nasopharyngeal-carcinoma-despite-access-challenges 2025-06-12T03:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/monopar-therapeutics-launches-fda-authorized-expanded-access-program-for-upar-targeted-radiopharmaceuticals-in-advanced-cancers 2025-06-12T01:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-partners-reports-promising-response-rates-with-optimized-mp0533-dosing-in-relapsed-refractory-aml 2025-06-12T01:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/skin-biopsy-test-detects-neurodegenerative-biomarker-in-75-of-rem-sleep-disorder-patients 2025-06-12T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/olaparib-temozolomide-combination-fails-to-improve-outcomes-in-advanced-uterine-leiomyosarcoma 2025-06-12T01:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-seeks-external-partners-to-fund-late-stage-vaccine-trials-for-latent-virus-programs 2025-06-12T01:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/university-at-buffalo-develops-novel-non-opioid-molecule-for-long-lasting-chronic-pain-relief 2025-06-12T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/ryght-ai-secures-3m-seed-funding-and-expands-academic-partnerships-to-accelerate-clinical-trial-site-selection 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-completes-11-2-billion-spin-off-from-novartis-becomes-independent-generics-leader 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-tamarack-biotics-uv-light-milk-treatment-technology-as-safe-alternative-to-traditional-pasteurization 2025-06-11T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-tablet-formulation-of-brukinsa-for-all-indications-reducing-pill-burden-for-b-cell-cancer-patients 2025-06-11T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-shows-no-benefit-and-potential-harm-in-colorectal-cancer-liver-metastases-phase-3-trial-finds 2025-06-11T21:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/t1d-exchange-to-present-13-real-world-data-studies-at-ada-2025-scientific-sessions 2025-06-11T21:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-s-eye-pain-drug-trial-ends-early-analysts-raise-price-target-60-on-accelerated-timeline 2025-06-11T21:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-to-present-next-generation-dendritic-cell-therapy-advances-at-cancer-immunotherapy-conference 2025-06-11T20:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/nusano-achieves-99-2-purity-in-gadolinium-160-enrichment-opens-190000-square-foot-utah-facility 2025-06-11T20:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-acquires-novel-prostate-cancer-radiopharmaceutical-for-1-35-billion 2025-06-11T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-appoints-kylie-o-keefe-as-chief-customer-and-strategy-officer-to-lead-amt-130-commercialization-for-huntington-s-disease 2025-06-11T20:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/biovica-sets-ambitious-revenue-targets-following-strategic-partnerships-in-cancer-monitoring 2025-06-11T20:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/sofinnova-partners-and-nvidia-launch-ai-infrastructure-partnership-to-accelerate-european-life-sciences-innovation 2025-06-11T18:00:17+00:00 hourly 0.9 https://trial.medpath.com/news/lifordi-presents-promising-preclinical-data-for-lfd-200-glucocorticoid-adc-at-eular-2025 2025-06-11T17:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/setpoint-medical-s-neuroimmune-modulation-platform-receives-eular-clinical-research-award-for-rheumatoid-arthritis-trial 2025-06-11T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-mavyret-as-first-treatment-for-acute-hepatitis-c-with-96-cure-rate-in-eight-weeks 2025-06-11T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/zeteo-biomedical-secures-global-patents-for-advanced-drug-delivery-technologies-supporting-space-based-healthcare 2025-06-11T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/nanobody-platform-enhances-cancer-immunotherapy-through-albumin-hitchhiking-and-sting-activation 2025-06-11T17:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/chiesi-group-and-key2brain-expand-partnership-with-worldwide-licensing-deal-for-blood-brain-barrier-crossing-therapies 2025-06-11T17:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-launches-public-offering-to-fund-car-t-cell-therapy-development-for-autoimmune-diseases 2025-06-11T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/graves-disease-pipeline-shows-promise-with-10-therapies-in-development-as-ted-treatments-gain-regulatory-momentum 2025-06-11T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/essilorluxottica-acquires-european-ophthalmology-network-optegra-to-advance-med-tech-strategy 2025-06-11T17:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/simtra-biopharma-solutions-and-milliporesigma-form-strategic-alliance-to-streamline-adc-manufacturing 2025-06-11T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/elkedonia-raises-eur11-25-million-to-develop-novel-neuroplastogen-therapy-for-treatment-resistant-depression 2025-06-11T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-bp1-15205-shows-breakthrough-potential-as-best-in-class-narcolepsy-treatment 2025-06-11T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/walnut-hill-medical-selected-as-fda-tap-program-advisor-to-accelerate-medical-device-patient-access 2025-06-11T17:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/seastar-medical-s-scd-therapy-receives-2-million-dod-grant-for-military-burn-and-sepsis-research 2025-06-11T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/medable-launches-ai-powered-partner-program-to-accelerate-clinical-trial-startup-by-50 2025-06-11T16:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-s-iopofosine-i-131-doubles-survival-in-pediatric-brain-cancer-trial 2025-06-11T16:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/energenesis-biomedical-advances-first-in-class-parkinson-s-disease-therapy-energi-f705pd-toward-phase-i-data-readout 2025-06-11T16:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/induction-chemoimmunotherapy-shows-non-inferior-outcomes-to-consolidation-therapy-in-stage-iii-nsclc 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-combines-personalized-neoantigen-vaccines-with-radiotherapy-for-advanced-cancer-treatment 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascend-advanced-therapies-achieves-gmp-certification-for-aav-gene-therapy-quality-control-in-munich 2025-06-11T15:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/cogent-biosciences-secures-400m-debt-financing-to-advance-bezuclastinib-through-pivotal-trials 2025-06-11T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/triplet-therapy-shows-superior-efficacy-in-braf-mutant-melanoma-brain-metastases 2025-06-11T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/capstan-therapeutics-initiates-first-in-human-trial-of-novel-in-vivo-car-t-therapy-for-autoimmune-diseases 2025-06-11T14:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytics-biotech-appoints-2b-deal-architect-as-ceo-to-advance-pelareorep-immunotherapy 2025-06-11T13:00:05+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-new-phase-3-trial-for-cagrisema-following-mixed-redefine-1-results 2025-06-11T12:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-s-nadunolimab-receives-fda-fast-track-designation-for-metastatic-pancreatic-cancer 2025-06-11T12:57:17+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-and-nvidia-launch-ai-orchestrator-agents-to-accelerate-clinical-research-and-drug-development 2025-06-11T12:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-demonstrates-therapeutic-antibodies-can-cross-kidney-barrier-supporting-bk-virus-treatment-approach 2025-06-11T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-researchers-develop-bioengineered-skin-graft-that-accelerates-burn-healing-by-50 2025-06-11T10:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-and-broad-institute-extend-cardiovascular-research-partnership-through-2030 2025-06-11T10:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-subsidiary-rayzebio-acquires-oncoacp3-radiopharmaceutical-for-prostate-cancer-in-1-35-billion-deal 2025-06-11T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/splicebio-raises-135-million-series-b-to-advance-first-dual-aav-gene-therapy-for-stargardt-disease 2025-06-11T10:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-in-class-influenza-drug-onradivir-targeting-novel-pb2-protein 2025-06-11T09:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/splicebio-raises-135-million-series-b-to-advance-gene-therapy-for-stargardt-disease-using-novel-protein-splicing-platform 2025-06-11T09:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/maxcyte-and-ori-biotech-partner-to-enhance-car-t-cell-manufacturing-through-platform-integration 2025-06-11T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1206-shows-promising-phase-1-results-in-combination-with-pembrolizumab-for-solid-tumors 2025-06-11T09:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/solvonis-therapeutics-launches-ai-powered-cns-drug-discovery-platform-for-depression-and-addiction 2025-06-11T09:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-partners-with-salipro-biotech-to-target-challenging-membrane-proteins-for-drug-discovery 2025-06-11T09:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/genepowerx-partners-with-mgi-tech-to-advance-ai-powered-genomic-solutions-for-personalized-medicine 2025-06-11T09:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/cadila-pharmaceuticals-launches-biscado-bisoprolol-to-address-india-s-cardiovascular-disease-burden 2025-06-11T08:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/hemab-therapeutics-advances-bleeding-disorder-pipeline-with-promising-clinical-data-at-isth-2025 2025-06-11T08:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/xl-protein-grants-worldwide-license-to-grifols-for-pasylation-enhanced-biopharmaceutical-development 2025-06-11T07:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/xprotm-shows-promise-in-reducing-alzheimer-s-pathology-following-traumatic-brain-injury-in-preclinical-study 2025-06-11T06:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-partners-with-carolinas-fertility-institute-to-expand-femaseed-access-across-north-carolina-network 2025-06-11T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/weekly-oral-risperidone-shows-promise-for-schizophrenia-treatment-in-phase-3-trial 2025-06-11T05:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/onesource-specialty-pharma-partners-with-xbrane-biopharma-for-commercial-biosimilar-manufacturing 2025-06-11T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/cyclopharm-secures-maximum-5-year-us-patent-extension-for-technegas-lung-imaging-agent-through-2031 2025-06-11T05:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/modified-dash-diet-shows-significant-blood-pressure-benefits-in-type-2-diabetes-patients 2025-06-11T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/angle-s-parsortix-system-enables-breakthrough-cancer-research-revealing-ctc-clusters-as-key-metastatic-drivers 2025-06-11T03:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/hypha-labs-advances-ai-powered-mushroom-cultivation-technology-with-new-patent-filings 2025-06-11T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/antibiotic-ciprofloxacin-shows-novel-ace-inhibition-mechanism-opening-path-to-improved-hypertension-therapies 2025-06-11T00:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/eli-health-raises-12m-series-a-to-commercialize-instant-saliva-based-hormone-monitoring-system 2025-06-11T00:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/network-meta-analysis-reveals-comparable-cardiovascular-benefits-between-pcsk9-inhibitors-alirocumab-and-evolocumab 2025-06-11T00:47:13+00:00 hourly 0.9 https://trial.medpath.com/news/sifi-merges-with-faes-farma-to-expand-global-access-to-akantior-first-approved-therapy-for-rare-eye-infection 2025-06-11T00:47:07+00:00 hourly 0.9 https://trial.medpath.com/news/us-universities-drive-87-of-academic-patents-supporting-fda-drug-approvals-from-2020-2024 2025-06-11T00:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-demonstrates-safety-and-efficacy-for-weight-loss-in-schizophrenia-patients 2025-06-11T00:46:54+00:00 hourly 0.9 https://trial.medpath.com/news/nicoya-lifesciences-acquires-applied-photophysics-to-create-integrated-biologics-characterization-platform 2025-06-11T00:46:51+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-mosunetuzumab-shows-promise-in-untreated-b-cell-lymphomas-with-durable-responses 2025-06-11T00:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/bexorg-partners-with-biohaven-to-advance-cns-drug-development-using-ai-driven-whole-brain-discovery-platform 2025-06-11T00:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/b-cell-depletion-therapy-shows-promise-for-nmosd-treatment-through-comprehensive-immune-system-modulation 2025-06-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/green-valley-pharmaceutical-suspends-production-of-controversial-alzheimer-s-drug-gv-971-amid-license-renewal 2025-06-10T21:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/us-small-molecule-api-cdmo-market-projected-to-reach-12-49-billion-by-2030-driven-by-fda-approvals-and-hpapi-demand 2025-06-10T19:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/nuevocor-receives-fda-ind-clearance-for-gene-therapy-targeting-rare-genetic-heart-disease 2025-06-10T18:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-manufacturing-issues-delay-unicycive-s-kidney-disease-drug-approval-process 2025-06-10T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-skyrizi-and-rinvoq-drive-recovery-as-humira-sales-plummet-50-following-patent-loss 2025-06-10T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/aiml-innovations-secures-provisional-patents-for-ai-powered-ecg-signal-processing-technology 2025-06-10T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-exercises-option-for-quell-s-car-treg-therapy-in-inflammatory-bowel-disease 2025-06-10T17:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-initiates-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china 2025-06-10T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-appoints-michael-vasconcelles-as-head-of-r-d-to-drive-pipeline-expansion 2025-06-10T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/curadev-and-memorial-sloan-kettering-expand-collaboration-to-advance-novel-sting-agonist-crd3874-si 2025-06-10T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/32-biosciences-secures-6-million-funding-to-advance-gut-microbiome-diagnostic-and-therapeutic-platform 2025-06-10T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-initiates-first-in-human-trial-of-personalized-aso-therapy-vca-894a-for-ultra-rare-cmt2s 2025-06-10T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-s-tpip-achieves-breakthrough-results-in-phase-2b-pah-trial-with-35-reduction-in-pulmonary-vascular-resistance 2025-06-10T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-unveils-cbl-514-preclinical-data-for-glp-1-weight-rebound-prevention-at-bio-2025 2025-06-10T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-therapeutics-receives-fda-clearance-for-mrt-8102-first-nek7-targeted-molecular-glue-degrader-for-inflammatory-diseases 2025-06-10T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-completes-first-in-class-ai-foundation-model-for-small-molecule-design-with-90-precision 2025-06-10T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/silicogenix-partners-with-bioduro-to-accelerate-ai-driven-drug-discovery-for-complex-diseases 2025-06-10T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/immvira-initiates-phase-ii-trial-for-novel-oncolytic-immunotherapy-in-bcg-unresponsive-bladder-cancer 2025-06-10T16:16:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-xifyrm-injectable-meloxicam-for-moderate-to-severe-pain-management 2025-06-10T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-gilead-s-weekly-hiv-combination-therapy-following-safety-signal 2025-06-10T16:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/hellocare-ai-partners-with-mayo-clinic-to-develop-ambient-clinical-intelligence-technology 2025-06-10T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/antares-therapeutics-launches-with-177-million-series-a-to-advance-first-in-class-cancer-precision-medicines 2025-06-10T14:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/centauri-therapeutics-demonstrates-novel-immunotherapy-approach-against-multi-drug-resistant-gram-negative-infections 2025-06-10T13:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-becomes-first-european-health-system-to-trial-revolutionary-histotripsy-cancer-treatment 2025-06-10T13:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/tagomics-secures-ps860k-grant-to-develop-novel-multiomics-test-for-early-colorectal-cancer-detection 2025-06-10T13:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/cellex-expands-gmp-manufacturing-capacity-following-production-of-over-5800-cell-and-gene-therapy-batches 2025-06-10T13:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/cn-bio-expands-fda-recognized-dili-assay-with-cross-species-models-to-improve-drug-safety-predictions 2025-06-10T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/emulate-launches-high-throughput-ava-system-to-replace-animal-testing-in-drug-development 2025-06-10T13:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-partners-with-virogen-to-advance-first-in-class-anti-cd3-immunotoxin-vg712-toward-commercial-manufacturing 2025-06-10T13:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/inflation-reduction-act-to-lower-btk-inhibitor-costs-potentially-transforming-cll-and-mcl-treatment-access 2025-06-10T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novoviah-s-novoleukintm-platform-achieves-90-sensitivity-in-celiac-disease-detection-through-novel-t-cell-testing 2025-06-10T10:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-denies-irhythm-patent-challenges-for-vital-signs-monitoring-technology 2025-06-10T08:46:52+00:00 hourly 0.9 https://trial.medpath.com/news/ezz-life-science-secures-21m-distribution-agreement-for-genomic-wellness-products-in-southeast-asia 2025-06-10T08:45:38+00:00 hourly 0.9 https://trial.medpath.com/news/smartphone-app-delivers-breakthrough-in-huntington-s-disease-clinical-trial-efficiency 2025-06-10T07:59:28+00:00 hourly 0.9 https://trial.medpath.com/news/renaissthera-advances-ai-designed-oral-obesity-drug-targeting-gipr-to-lead-optimization 2025-06-10T06:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/alexion-partners-with-pangaea-data-to-develop-ai-system-for-hypophosphatasia-detection 2025-06-10T05:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/taconic-biosciences-secures-exclusive-crispr-license-from-helmholtz-munich-to-enhance-animal-model-generation 2025-06-10T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-syntara-s-snt-5505-for-myelofibrosis-treatment 2025-06-10T05:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-secures-70-million-in-zynyz-royalty-deal-extends-cash-runway-through-2027 2025-06-10T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-of-niraparib-dostarlimab-combination-fails-to-meet-primary-endpoint-in-recurrent-head-and-neck-cancer 2025-06-10T03:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/national-resilience-winds-down-six-manufacturing-facilities-despite-2-25-billion-in-total-funding 2025-06-10T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/aribio-and-arcera-forge-600-million-partnership-for-novel-alzheimer-s-drug-ar1001 2025-06-10T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/sentio-biosciences-announces-10-6-million-expansion-to-boost-domestic-generic-drug-manufacturing 2025-06-10T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/cgas-sting-pathway-shows-dual-role-in-breast-cancer-immunotherapy-response 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nordic-capital-invests-in-minerva-imaging-to-build-global-radiopharmaceutical-platform 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/efgartigimod-shows-promise-in-treating-rare-neurological-autoimmune-disorders-beyond-myasthenia-gravis 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-to-present-phase-1-results-of-next-generation-obesity-drugs-at-ada-2025 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/walmart-launches-healthcare-research-institute-to-expand-clinical-trial-access-and-diversity 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/resonant-clinical-solutions-names-christophe-berthoux-as-ceo-to-drive-global-expansion 2025-06-09T22:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/glycovax-pharma-launches-commercial-production-of-affordable-crm197-protein-for-conjugate-vaccines 2025-06-09T22:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-reports-statistically-significant-results-in-breast-cancer-subgroup-from-phase-3-ontarget-trial 2025-06-09T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-agrees-vivavision-s-phase-2-trial-can-serve-as-pivotal-study-for-vvn461ld-eye-drop 2025-06-09T21:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/eluminex-biosciences-reports-positive-phase-1b-results-for-novel-pentavalent-antibody-eb-105-in-diabetic-macular-edema 2025-06-09T21:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/tang-capital-s-concentra-biosciences-acquires-elevation-oncology-for-0-36-per-share-in-latest-biotech-liquidation 2025-06-09T21:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/collplant-expands-stemcell-technologies-partnership-to-include-clinical-and-commercial-applications-of-plant-derived-collagen 2025-06-09T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-prepares-to-present-pediatric-inhaled-insulin-data-at-ada-scientific-sessions 2025-06-09T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-merck-s-enflonsia-for-rsv-prevention-in-infants-with-single-weight-independent-dose 2025-06-09T20:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-validates-clinical-trial-outcomes-in-advanced-urothelial-carcinoma-treatment 2025-06-09T20:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/psilera-partners-with-hesperos-to-advance-organ-on-a-chip-testing-for-frontotemporal-dementia-drug 2025-06-09T19:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-to-acquire-elevation-oncology-for-0-36-per-share-plus-contingent-value-rights 2025-06-09T17:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/scottish-health-authority-rejects-alzheimer-s-drug-donanemab-despite-uk-regulatory-approval 2025-06-09T17:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-through-extracellular-vesicle-removal 2025-06-09T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/electric-fields-combined-with-immunotherapy-show-70-survival-improvement-in-glioblastoma-patients 2025-06-09T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/mosanna-therapeutics-secures-80m-series-a-to-advance-nasal-spray-treatment-for-obstructive-sleep-apnea 2025-06-09T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/rxmp-therapeutics-advances-hemostatic-agent-rmp-402-with-dod-partnership-and-fda-manufacturing-approval 2025-06-09T17:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/axio-biopharma-and-likarda-form-strategic-partnership-to-integrate-ai-manufacturing-with-advanced-drug-delivery 2025-06-09T17:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/gl-chemtec-completes-state-of-the-art-gmp-facility-to-accelerate-clinical-trial-material-production 2025-06-09T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-s-tqc3721-inhalation-drug-receives-phase-iii-approval-for-copd-treatment 2025-06-09T17:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/neowise-biotechnology-partners-with-beone-medicines-to-advance-ipsc-based-off-the-shelf-cell-therapies 2025-06-09T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/fable-therapeutics-appoints-former-astrazeneca-executive-david-j-baker-as-chief-scientific-officer 2025-06-09T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/innospera-pharma-appoints-dr-glenn-crater-as-chief-medical-officer-to-advance-ipf-drug-ing-006 2025-06-09T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/complement-1-raises-16m-to-scale-ai-powered-cancer-lifestyle-platform-with-90-patient-adherence 2025-06-09T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/olanzapine-shows-promise-in-preventing-radiation-induced-nausea-and-vomiting-in-phase-3-trial 2025-06-09T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-appoints-gene-therapy-veteran-dr-daniel-chung-as-chief-medical-officer 2025-06-09T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/citius-oncology-partners-with-cardinal-health-for-lymphir-distribution-ahead-of-commercial-launch 2025-06-09T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/tybr-health-secures-fda-510-k-clearance-for-b3-gel-system-to-protect-healing-tissues-in-musculoskeletal-surgery 2025-06-09T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/avanzanite-partners-with-agios-to-commercialize-first-in-class-pyruvate-kinase-activator-across-europe 2025-06-09T17:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-hla-g-targeted-exosome-therapy-sob100-receives-fda-approval-for-phase-i-cancer-trials 2025-06-09T16:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/circuit-clinical-and-lightship-merge-to-transform-clinical-trial-access-and-delivery 2025-06-09T16:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-analysis-reveals-brca1-mutation-drives-distinct-tumor-microenvironments-in-triple-negative-breast-cancer 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-factors-drive-early-b-cell-repletion-after-anti-cd20-therapy-in-african-american-ms-patients 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-breaks-ground-on-china-s-first-dual-chamber-lyophilization-manufacturing-site-in-chengdu 2025-06-09T15:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-plus-chemotherapy-demonstrates-five-year-survival-benefit-in-resectable-nsclc 2025-06-09T14:59:41+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapeutic-classes-transform-future-treatment-paradigm-for-metastatic-castration-resistant-prostate-cancer 2025-06-09T13:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipocine-s-partner-files-new-drug-submission-for-tlando-in-canada-targeting-700000-annual-trt-prescriptions 2025-06-09T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-arizona-researchers-identify-drug-candidate-that-reverses-heart-failure-progression-in-mouse-models 2025-06-09T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-secures-new-u-s-patent-for-aversa-abuse-deterrent-transdermal-technology 2025-06-09T13:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/metsera-s-met-233i-achieves-8-4-weight-loss-in-phase-1-trial-enabling-first-monthly-amylin-glp-1-combination 2025-06-09T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/secura-bio-initiates-phase-3-terzo-trial-of-copiktra-for-rare-t-cell-lymphoma 2025-06-09T13:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-appoints-dr-bill-desmarais-as-cfo-and-cbo-to-advance-targeted-protein-degradation-pipeline 2025-06-09T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/anlotinib-plus-immune-checkpoint-inhibitors-shows-promise-in-previously-treated-extensive-stage-small-cell-lung-cancer 2025-06-09T13:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-and-recibiopharm-expand-malaria-vaccine-partnership-to-advance-two-blood-stage-candidates 2025-06-09T13:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/ionq-achieves-20-fold-speedup-in-drug-discovery-simulations-through-quantum-classical-hybrid-computing 2025-06-09T13:00:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-reviews-chickenpox-vaccines-after-fatal-encephalitis-case-in-polish-child 2025-06-09T12:59:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-axsome-s-fibromyalgia-drug-application-due-to-trial-design-issues 2025-06-09T12:58:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-triple-combination-hypertension-drug-widaplik-for-initial-treatment 2025-06-09T12:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/statins-show-39-mortality-reduction-in-sepsis-patients-large-study-reveals 2025-06-09T12:58:27+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-enlicitide-shows-promise-as-first-oral-pcsk9-inhibitor-in-phase-3-trials 2025-06-09T12:58:23+00:00 hourly 0.9 https://trial.medpath.com/news/metsera-s-monthly-amylin-injection-achieves-8-4-weight-loss-in-phase-i-trial 2025-06-09T12:58:17+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharmaceuticals-receives-dcgi-approval-to-launch-brukinsa-for-five-b-cell-malignancies-in-india 2025-06-09T08:58:28+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-reports-promising-phase-1b-2a-results-for-ever001-btk-inhibitor-in-primary-membranous-nephropathy 2025-06-09T08:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/ema-extends-shelf-life-of-veterinary-cancer-drug-masivet-to-48-months 2025-06-09T08:57:50+00:00 hourly 0.9 https://trial.medpath.com/news/advent-international-invests-175-million-in-animal-health-generics-company-felix-pharmaceuticals 2025-06-09T08:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/philippines-fda-expands-vat-free-medicine-list-to-include-new-cancer-diabetes-and-cardiovascular-treatments 2025-06-09T05:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-challenges-vera-therapeutics-in-kidney-disease-race-as-glp-1-drugs-face-eye-safety-scrutiny 2025-06-09T05:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-partners-with-nipro-to-commercialize-biosimilars-in-japan-including-ustekinumab-candidate 2025-06-09T02:56:46+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-gvhd-treatment-evolution-biomarker-guided-therapy-and-steroid-free-approaches-show-promise 2025-06-09T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-gene-therapy-and-bbb-penetrating-treatments-transform-hunter-syndrome-treatment-landscape 2025-06-08T22:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/four-promising-gene-and-cell-therapies-challenge-aldurazyme-s-dominance-in-mps-i-treatment 2025-06-08T20:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-eyes-combination-therapy-to-set-new-standard-for-obesity-treatment 2025-06-08T13:46:28+00:00 hourly 0.9 https://trial.medpath.com/news/carboplatin-addition-to-standard-chemotherapy-shows-no-survival-benefit-in-triple-negative-breast-cancer 2025-06-08T08:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/uk-doctors-trial-freeze-dried-fecal-microbiota-pills-to-combat-antibiotic-resistant-superbugs 2025-06-08T04:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-two-drug-candidates-for-ultra-rare-x-linked-myopathy-using-zebrafish-model 2025-06-08T04:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-elamipretide-for-rare-mitochondrial-disease-despite-patient-improvements 2025-06-08T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-universities-launch-clinical-trials-testing-psychedelics-for-treatment-resistant-mental-health-disorders 2025-06-07T22:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/uc-berkeley-awards-200000-venture-grant-to-hypo2regen-therapeutics-with-future-investment-option 2025-06-07T21:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/serve-you-rx-adds-two-ustekinumab-biosimilars-to-formulary-offering-up-to-96-cost-savings 2025-06-07T18:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/empagliflozin-demonstrates-kidney-safety-across-multiple-patient-populations-new-pooled-analysis-shows 2025-06-07T17:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/il-12-modified-mrna-vaccines-demonstrate-enhanced-t-cell-activation-in-university-of-pennsylvania-study 2025-06-07T16:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-moderna-s-next-generation-covid-19-vaccine-mrna-1283-with-enhanced-efficacy 2025-06-07T16:45:53+00:00 hourly 0.9 https://trial.medpath.com/news/zhengye-biotechnology-completes-6-million-ipo-as-chinese-veterinary-vaccine-manufacturer-enters-us-markets 2025-06-07T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-trial-shows-spironolactone-fails-to-reduce-cardiovascular-risk-in-dialysis-patients 2025-06-07T13:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-5000-crore-prip-scheme-signals-major-shift-from-generic-manufacturing-to-innovation-led-pharma-growth 2025-06-07T12:46:45+00:00 hourly 0.9 https://trial.medpath.com/news/new-screening-algorithms-and-diagnostic-approaches-aim-to-reduce-pulmonary-arterial-hypertension-detection-delays 2025-06-07T12:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-first-of-its-kind-antibody-drug-conjugate-for-multiple-myeloma-treatment 2025-06-07T09:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-raises-safety-concerns-about-fecal-microbiota-transplants 2025-06-07T08:59:26+00:00 hourly 0.9 https://trial.medpath.com/news/uconn-researchers-develop-novel-nanoparticle-mrna-vaccine-platform-for-infectious-bronchitis-virus-in-poultry 2025-06-07T04:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacist-led-interventions-generate-9-million-in-cancer-care-cost-savings-through-remote-clinical-reviews 2025-06-07T03:00:15+00:00 hourly 0.9 https://trial.medpath.com/news/acip-members-face-termination-as-rfk-jr-s-vaccine-policy-changes-spark-institutional-upheaval 2025-06-07T02:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/high-placebo-response-rates-challenge-lupus-drug-development-as-researchers-develop-new-trial-strategies 2025-06-07T02:59:34+00:00 hourly 0.9 https://trial.medpath.com/news/mission-bio-secures-funding-to-advance-single-cell-tri-omics-platform-for-cancer-drug-development 2025-06-07T02:59:26+00:00 hourly 0.9 https://trial.medpath.com/news/first-ascent-biomedical-partners-with-fight-colorectal-cancer-for-350000-precision-medicine-study 2025-06-07T01:59:20+00:00 hourly 0.9 https://trial.medpath.com/news/church-dwight-recalls-zicam-and-orajel-nasal-swabs-due-to-fungal-contamination-risk 2025-06-07T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-immunotherapy-plus-chemotherapy-improves-long-term-survival-in-operable-nsclc 2025-06-07T01:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/powers-health-partners-with-profound-research-to-establish-clinical-research-center-in-northwest-indiana 2025-06-07T00:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-raises-mid-term-sales-outlook-to-6-growth-through-2029-on-pipeline-strength 2025-06-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nkarta-appoints-immunology-expert-shawn-rose-as-chief-medical-officer-to-lead-autoimmune-nk-cell-therapy-development 2025-06-06T20:50:23+00:00 hourly 0.9 https://trial.medpath.com/news/brenntag-specialties-acquires-czech-firm-mcepharma-to-expand-gmp-capabilities-across-emea-region 2025-06-06T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cancels-766-million-mrna-bird-flu-vaccine-contract-with-moderna 2025-06-06T20:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-transfers-66-million-patent-dispute-between-alkermes-and-acorda-therapeutics 2025-06-06T20:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/bionet-and-bio-farma-partner-to-accelerate-tdap-vaccine-access-across-southeast-asia 2025-06-06T20:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/major-pbms-exclude-humira-biosimilars-from-2025-formularies-favor-private-label-products 2025-06-06T20:47:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-kura-oncology-s-nda-for-ziftomenib-in-npm1-mutant-aml-with-priority-review 2025-06-06T20:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-integration-and-advanced-drug-delivery-systems-reshape-pharmaceutical-outsourcing-models 2025-06-06T20:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/transcatheter-pda-closure-shows-comparable-respiratory-outcomes-to-surgery-in-preterm-infants 2025-06-06T20:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-phathom-pharmaceuticals-10-year-market-exclusivity-for-voquezna-through-2032 2025-06-06T20:46:34+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-raises-250-million-in-largest-hong-kong-biopharma-follow-on-offering-in-12-months 2025-06-06T19:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-s-sibeprenlimab-achieves-51-reduction-in-proteinuria-for-iga-nephropathy-intensifying-competition-with-vera-therapeutics 2025-06-06T18:58:15+00:00 hourly 0.9 https://trial.medpath.com/news/fidaxomicin-demonstrates-superior-efficacy-in-reducing-c-difficile-recurrence-among-high-risk-patients 2025-06-06T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-to-present-phase-3-hemophilia-trial-data-at-isth-2025-congress 2025-06-06T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/mckesson-corporation-completes-acquisition-of-florida-cancer-specialists-to-strengthen-community-oncology-network 2025-06-06T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-strengthens-board-with-industry-veteran-ahead-of-key-bla-submission 2025-06-06T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-unveils-advanced-sterile-manufacturing-facility-to-boost-biologic-production-capacity 2025-06-06T17:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/mit-and-recursion-release-boltz-2-open-source-ai-model-achieves-1000x-speed-boost-in-drug-discovery-screening 2025-06-06T17:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/vivoryon-s-varoglutamstat-shows-sustained-kidney-function-improvement-in-phase-2-meta-analysis 2025-06-06T17:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/aytu-biopharma-secures-exclusive-rights-to-first-in-class-antidepressant-exxua-for-22b-us-market 2025-06-06T17:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/aytu-biopharma-raises-16-6m-to-launch-first-in-class-depression-treatment-exxua 2025-06-06T16:59:27+00:00 hourly 0.9 https://trial.medpath.com/news/nemluvio-shows-sustained-long-term-efficacy-in-atopic-dermatitis-with-two-year-extension-data 2025-06-06T13:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/denovo-biopharma-forms-neuroscience-advisory-board-to-advance-precision-medicine-approach-for-treatment-resistant-depression 2025-06-06T13:00:37+00:00 hourly 0.9 https://trial.medpath.com/news/glycomimetics-stockholders-approve-merger-with-crescent-biopharma-creating-new-oncology-focused-entity 2025-06-06T13:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-biopharma-sector-showcases-innovation-leadership-at-bioseedin-2025-conference 2025-06-06T12:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/htl-biotechnology-launches-eur12-million-sterile-hyaluronic-acid-production-line-to-enable-heat-sensitive-drug-combinations 2025-06-06T12:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-doses-first-patient-in-world-s-first-in-vivo-crispr-trial-for-tgfbi-corneal-dystrophy 2025-06-06T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/immune-thrombocytopenia-presents-diagnostic-challenges-with-unpredictable-disease-course 2025-06-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bitbiome-partners-with-leading-cmo-to-enable-large-scale-biomanufacturing-of-microbial-derived-products 2025-06-06T11:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/pyx-health-acquires-farmboxrx-in-47-5m-deal-to-combat-health-disparities-through-food-based-care 2025-06-06T09:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/hemispherian-s-glix1-receives-ema-orphan-drug-designation-for-glioma-treatment 2025-06-06T09:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/penumbra-launches-ruby-xl-system-the-largest-embolization-coil-platform-for-vascular-procedures 2025-06-06T09:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/elgan-pharma-and-chiesi-begin-phase-3-trial-of-elgn-2112-for-intestinal-malabsorption-in-preterm-infants 2025-06-06T09:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/improved-pharma-completes-fifth-expansion-at-kurz-purdue-technology-center-now-occupying-over-5500-square-feet 2025-06-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-receives-regulatory-approval-for-triple-combination-cancer-therapy-trial 2025-06-06T07:00:06+00:00 hourly 0.9 https://trial.medpath.com/news/abilitypharma-s-ibrilatazar-doubles-overall-survival-in-squamous-non-small-cell-lung-cancer-trial 2025-06-06T05:58:12+00:00 hourly 0.9 https://trial.medpath.com/news/foldax-receives-world-s-first-approval-for-polymer-heart-valve-in-india 2025-06-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-injectable-antipsychotics-proposed-as-new-standard-of-care-for-schizophrenia-treatment 2025-06-06T04:58:54+00:00 hourly 0.9 https://trial.medpath.com/news/prophase-labs-forms-clinical-advisory-board-to-advance-be-smart-esophageal-cancer-diagnostic-platform 2025-06-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seyltx-advances-chronic-cough-pipeline-with-optimized-ifenprodil-dosing-and-strategic-neurop-partnership 2025-06-06T03:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/insurance-prior-authorization-delays-cancer-treatment-by-up-to-two-weeks-forcing-suboptimal-care-decisions 2025-06-06T03:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharma-presents-72-studies-at-asco-2025-demonstrating-broad-oncology-pipeline-impact 2025-06-06T03:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/adolescent-obesity-medication-prescriptions-surge-301-despite-persistent-access-barriers 2025-06-06T02:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-s-padeliporfin-vtp-therapy-enables-surgical-resection-in-previously-inoperable-pancreatic-cancer-patient 2025-06-06T00:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-tecentriq-cuts-colon-cancer-recurrence-by-50-in-patients-with-dna-repair-defects 2025-06-06T00:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/lenacapavir-shows-100-efficacy-in-hiv-prevention-with-twice-yearly-injection 2025-06-06T00:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-clarus-700-ultra-widefield-retinal-imaging-system-receives-nmpa-approval-in-china 2025-06-06T00:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/signify-bio-launches-with-15m-funding-to-develop-in-situ-protein-therapeutics-platform 2025-06-06T00:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-gras-clearance-for-omniactive-s-lutemax-free-lutein-in-infant-formula 2025-06-06T00:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/inka-health-launches-global-ai-oncology-consortium-to-advance-predictive-cancer-research 2025-06-06T00:47:16+00:00 hourly 0.9 https://trial.medpath.com/news/bytebrain-launches-medrail-ai-platform-to-transform-clinical-trial-operations 2025-06-06T00:46:07+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-s-bioengineered-vessel-shows-superior-performance-in-high-risk-dialysis-patients 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-faces-major-setback-as-cell-therapy-amtagvi-commercial-launch-struggles 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-medtronic-s-enhanced-visualase-v2-mri-guided-laser-ablation-system-for-brain-surgery 2025-06-05T23:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/p2y12-inhibitors-show-23-reduction-in-cardiovascular-events-compared-to-aspirin-in-post-stent-patients 2025-06-05T22:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-ai-tool-elsa-for-drug-reviews-while-novo-nordisk-struggles-in-obesity-market-competition 2025-06-05T22:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/first-clinical-trial-shows-nicotinamide-riboside-improves-multiple-health-outcomes-in-werner-syndrome-patients 2025-06-05T22:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/nrg-oncology-trial-shows-regional-nodal-radiation-provides-no-benefit-for-breast-cancer-patients-with-node-conversion-after-neoadjuvant-chemotherapy 2025-06-05T22:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-study-shows-81-success-rate-for-pfo-closure-in-drug-resistant-migraine-patients 2025-06-05T21:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/kennedy-pledges-accelerated-fda-approvals-for-rare-disease-therapies-to-maintain-us-biotech-leadership 2025-06-05T20:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/plt-health-solutions-serezin-shows-significant-sleep-and-pain-relief-benefits-in-clinical-trial 2025-06-05T20:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/cns-pharmaceuticals-presents-brain-penetrating-taxane-tpi-287-for-glioblastoma-treatment-at-2025-brain-tumor-summit 2025-06-05T20:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-s-fabp5-inhibitor-art26-12-shows-comparable-efficacy-to-naproxen-in-osteoarthritis-pain-study 2025-06-05T19:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/dr-elizabeth-mittendorf-outlines-vision-as-asco-president-elect-to-advance-multidisciplinary-cancer-care-and-workforce-support 2025-06-05T17:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/upstream-bio-presents-data-showing-verekitug-s-superior-potency-through-tslp-receptor-targeting-at-eaaci-congress 2025-06-05T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-s-chikungunya-vaccine-shows-sustained-antibody-response-in-children-after-six-months 2025-06-05T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/casma-therapeutics-nominates-first-in-class-trpml1-agonist-csm-101-for-parkinson-s-disease-treatment 2025-06-05T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/qurebio-secures-14-million-series-c1-funding-to-advance-bispecific-antibody-pipeline 2025-06-05T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/allay-therapeutics-secures-57-5m-series-d-to-advance-ultra-sustained-pain-management-platform 2025-06-05T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/linear-diagnostics-secures-ps1m-to-advance-5-minute-sti-diagnostic-test 2025-06-05T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/mandatory-human-abuse-liability-assessment-reshapes-drug-development-strategy-and-regulatory-compliance 2025-06-05T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/iperionx-secures-99m-defense-contract-for-domestic-titanium-manufacturing 2025-06-05T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/veongen-therapeutics-receives-fda-rare-pediatric-disease-designation-for-stargardt-disease-gene-therapy-vg801 2025-06-05T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-immunotherapeutics-surges-104-following-italian-regulatory-clearance-for-pincell-acquisition 2025-06-05T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/uk-drug-regulator-issues-first-contraception-warning-for-weight-loss-injections-after-40-pregnancy-reports 2025-06-05T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-achieves-ai-driven-breakthrough-in-universal-dengue-vaccine-discovery 2025-06-05T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/cresemba-antifungal-drug-achieves-record-global-sales-triggers-2-5m-milestone-payment-to-basilea 2025-06-05T15:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/osivax-completes-phase-2a-booster-trial-for-broad-spectrum-influenza-vaccine-ovx836 2025-06-05T14:59:10+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-raises-2-5-million-through-warrant-exercise-to-advance-cancer-drug-development 2025-06-05T14:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-achieves-breakthrough-in-targeted-nanoparticle-development-for-universal-cancer-treatment 2025-06-05T12:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-secures-japan-patent-for-renmab-platform-strengthening-global-ip-portfolio-for-fully-human-antibody-discovery 2025-06-05T12:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-secures-patent-protection-for-wakix-through-2030-settlement-with-lupin 2025-06-05T12:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondrial-dna-variant-predicts-immunotherapy-resistance-in-metastatic-melanoma 2025-06-05T12:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/mediar-therapeutics-initiates-phase-2-trial-of-first-in-class-anti-wisp1-antibody-for-idiopathic-pulmonary-fibrosis 2025-06-05T12:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/kiniksa-pharmaceuticals-advances-kpl-387-phase-2-3-trial-for-recurrent-pericarditis 2025-06-05T12:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/juvenescence-acquires-ai-drug-discovery-company-ro5-to-accelerate-age-related-disease-pipeline 2025-06-05T12:45:29+00:00 hourly 0.9 https://trial.medpath.com/news/confidence-study-shows-superior-kidney-protection-with-combined-finerenone-and-sglt-2-inhibitor-therapy 2025-06-05T12:44:48+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-partners-with-senju-for-kio-301-development-in-asian-markets-worth-over-110-million 2025-06-05T12:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/bnt327-pm8002-bispecific-antibody-shows-promising-activity-in-unresectable-mesothelioma 2025-06-05T12:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-secures-161m-gene-therapy-licensing-deal-for-ocu400-in-korean-market 2025-06-05T12:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/servier-india-launches-first-in-class-idh1-targeted-therapy-ivosidenib-for-rare-blood-and-bile-duct-cancers 2025-06-05T12:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-hundreds-of-drugs-without-adequate-evidence-of-effectiveness-investigation-reveals 2025-06-05T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-researchers-pioneer-multiomics-based-cancer-treatment-predictions-in-first-of-kind-clinical-study 2025-06-05T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-partners-with-stanford-medicine-to-advance-ultrasensitive-infectious-disease-diagnostics 2025-06-05T10:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-64cu-sartate-shows-superior-lesion-detection-in-phase-ii-disco-trial-for-neuroendocrine-tumors 2025-06-05T10:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-licenses-bcma-targeted-bispecific-t-cell-engager-for-autoimmune-disease-development 2025-06-05T09:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-cancer-therapy-pipeline-shows-strong-growth-with-120-companies-developing-125-treatments 2025-06-05T09:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/kancera-receives-fda-fast-track-eligibility-for-kand567-in-heart-attack-treatment 2025-06-05T08:58:50+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-and-alvotech-partner-to-develop-keytruda-biosimilar-in-29-5-billion-market 2025-06-05T08:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/mgi-tech-expands-partnership-with-brazil-s-fiocruz-to-enhance-genetic-sequencing-for-cancer-and-infectious-disease-diagnostics 2025-06-05T08:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/melbourne-researchers-develop-mrna-technology-to-force-hiv-out-of-cellular-hiding-places 2025-06-05T08:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-s-ranivisio-becomes-first-lucentis-biosimilar-approved-in-brazil 2025-06-05T08:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/astrivax-therapeutics-launches-phase-i-trial-of-avx70371-hepatitis-b-immunotherapy 2025-06-05T08:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/livanova-s-core-vns-study-demonstrates-sustained-seizure-reduction-in-drug-resistant-epilepsy-patients 2025-06-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/metsera-to-showcase-next-generation-obesity-therapies-at-ada-2025-with-clinical-data-from-ultra-long-acting-glp-1-agonist 2025-06-05T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-of-methotrexate-safety-profile-reveals-gender-and-age-specific-adverse-event-patterns 2025-06-05T07:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/unf-researchers-advance-cancer-fighting-compound-to-animal-trials-after-breakthrough-discovery 2025-06-05T06:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/acerand-therapeutics-initiates-first-in-human-trial-of-novel-cyp11a1-inhibitor-ace-232-for-advanced-prostate-cancer 2025-06-05T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/openwater-s-portable-stroke-detection-device-shows-promise-in-field-diagnostics-and-rehabilitation-research 2025-06-05T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-denies-approval-for-elamipretide-forcing-stealth-biotherapeutics-to-halt-production-of-rare-disease-treatment 2025-06-05T05:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/tivozanib-monotherapy-shows-promise-as-second-line-treatment-for-metastatic-rcc-following-contemporary-immunotherapy 2025-06-05T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/terthera-launches-world-s-first-gmp-compliant-terbium-161-for-enhanced-cancer-radiotherapy 2025-06-05T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/mallia-completes-eur5-5m-seed-funding-to-advance-scd83-based-hair-loss-treatments 2025-06-05T03:57:08+00:00 hourly 0.9 https://trial.medpath.com/news/rakuten-medical-secures-amed-funding-for-novel-pd-l1-photoimmunotherapy-rm-0256 2025-06-05T03:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/nucleus-genomics-launches-first-genetic-optimization-software-for-ivf-embryo-selection 2025-06-05T03:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-model-outperforms-individual-biomarkers-in-predicting-advanced-renal-cell-carcinoma-treatment-response 2025-06-05T02:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/ret-inhibitor-rechallenge-shows-promise-in-pre-treated-nsclc-patients-after-toxicity-related-discontinuation 2025-06-05T01:57:16+00:00 hourly 0.9 https://trial.medpath.com/news/mycovia-pharmaceuticals-initiates-phase-2-trial-of-oteseconazole-for-cryptococcal-meningitis 2025-06-05T01:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/toyobo-and-dmc-biotechnologies-partner-to-develop-sustainable-chemical-intermediates-through-precision-fermentation 2025-06-05T01:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/zigakibart-shows-sustained-60-proteinuria-reduction-in-100-week-iga-nephropathy-study 2025-06-05T01:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-milli-spinner-technology-that-doubles-blood-clot-removal-effectiveness 2025-06-05T01:01:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-breakthrough-accelerates-protein-engineering-for-next-generation-therapeutics 2025-06-05T00:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/bnt113-cancer-vaccine-shows-promise-in-phase-ii-iii-trial-for-hpv16-head-and-neck-cancer 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-acquires-sumitomo-s-canadian-portfolio-including-myfembree-and-orgovyx-for-c-25-4-million 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/highridge-medical-divests-bone-healing-division-to-focus-on-core-spine-technologies 2025-06-04T23:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-launches-enhanced-trinav-flx-infusion-system-for-improved-tumor-drug-delivery 2025-06-04T23:55:45+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-medical-care-advances-u-s-rollout-of-high-volume-hemodiafiltration-following-fda-clearance 2025-06-04T22:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/elucidata-and-sapien-biosciences-form-strategic-partnership-to-transform-india-s-largest-biobank-into-ai-ready-data-platform 2025-06-04T22:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/aitia-partners-with-gustave-roussy-to-develop-ai-powered-digital-twins-for-cancer-research 2025-06-04T21:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-reveals-complex-effects-of-ozempic-on-muscle-mass-and-strength 2025-06-04T21:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-s-new-ceo-charts-course-for-adc-expansion-beyond-enhertu-success 2025-06-04T20:56:35+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-moderna-victory-in-covid-19-vaccine-patent-dispute-with-alnylam 2025-06-04T20:56:15+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-funding-plummets-57-to-2-7-billion-as-trump-administration-policies-shake-investor-confidence 2025-06-04T20:54:53+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-gsk-pursue-aggressive-m-a-strategies-while-mrna-technology-faces-economic-headwinds 2025-06-04T20:53:27+00:00 hourly 0.9 https://trial.medpath.com/news/thio-plus-cemiplimab-demonstrates-promising-activity-in-ici-resistant-advanced-nsclc 2025-06-04T20:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/kfshrc-achieves-breakthrough-in-gene-therapy-for-hemophilia-a-with-one-time-treatment-success 2025-06-04T20:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/china-courts-signal-shift-in-polymorph-patent-standards-as-beijing-ip-court-lowers-inventiveness-bar 2025-06-04T20:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-awards-sarepta-first-platform-technology-designation-for-gene-therapy-vector 2025-06-04T18:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/carbogen-amcis-secures-chf-25-million-co-investment-to-expand-adc-drug-linker-manufacturing-in-switzerland 2025-06-04T17:58:45+00:00 hourly 0.9 https://trial.medpath.com/news/cepheid-receives-health-canada-approval-for-next-generation-hiv-viral-load-test 2025-06-04T17:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/vividion-secures-exclusive-rights-to-first-in-class-wrn-inhibitor-vvd-214-for-msi-high-cancers 2025-06-04T16:56:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-drug-free-wearable-device-for-pediatric-nasal-congestion-treatment 2025-06-04T16:55:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-oncology-trials-rarely-demonstrate-meaningful-survival-and-quality-of-life-improvements 2025-06-04T16:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/iambic-therapeutics-advances-ai-designed-her2-inhibitor-iam1363-to-dose-optimization-phase 2025-06-04T16:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/eib-provides-eur30m-to-treefrog-therapeutics-for-parkinson-s-disease-cell-therapy-development 2025-06-04T16:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-and-nanjing-chia-tai-tianqing-receive-ind-approval-for-second-generation-anti-igf-1r-antibody-ntb003-in-thyroid-eye-disease 2025-06-04T16:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/oncovita-receives-fda-orphan-drug-designation-for-oncolytic-measles-virus-therapy-in-pleural-mesothelioma 2025-06-04T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/carbogen-amcis-shanghai-facility-receives-first-drug-manufacturing-license-from-china-s-nmpa 2025-06-04T16:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/repertoire-immune-medicines-appoints-oncology-veteran-as-cmo-advances-tcr-bispecific-toward-phase-1-2-trial 2025-06-04T16:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/lipella-pharmaceuticals-renews-manufacturing-partnership-with-cook-myosite-to-advance-oral-lichen-planus-treatment 2025-06-04T16:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/usp-opens-advanced-technologies-laboratory-to-strengthen-pharmaceutical-supply-chains-and-manufacturing 2025-06-04T16:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-launches-firstgene-multiple-prenatal-screen-with-four-in-one-testing-capability 2025-06-04T16:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/vadadustat-phase-3-data-reveals-geographic-differences-in-ckd-anemia-treatment-outcomes 2025-06-04T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-strategic-recommendations-to-address-critical-radiopharmaceutical-supply-chain-vulnerabilities-in-europe 2025-06-04T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-issues-first-uk-guidance-for-phage-therapy-development-to-combat-antibiotic-resistant-infections 2025-06-04T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-kabi-launches-first-generic-iodixanol-contrast-agent-in-canada-addressing-critical-supply-shortages 2025-06-04T16:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/annamycin-shows-59-clinical-benefit-rate-in-soft-tissue-sarcoma-lung-metastases-phase-2-trial 2025-06-04T16:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/halia-therapeutics-completes-enrollment-in-phase-2a-trial-of-novel-nlrp3-inflammasome-inhibitor-for-myelodysplastic-syndrome 2025-06-04T16:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/biodexa-initiates-phase-2-trial-of-tolimidone-for-type-1-diabetes-treatment 2025-06-04T16:45:49+00:00 hourly 0.9 https://trial.medpath.com/news/commit-biologics-forms-scientific-advisory-board-to-advance-complement-based-cancer-and-autoimmune-therapies 2025-06-04T14:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/tata-memorial-centre-partners-with-ge-healthcare-to-establish-advanced-cancer-research-innovation-centre 2025-06-04T12:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-acquires-focal-medical-to-advance-iontophoresis-based-pancreatic-cancer-therapy 2025-06-04T12:58:20+00:00 hourly 0.9 https://trial.medpath.com/news/buscar-company-acquires-70-stake-in-armorgenix-to-enter-pharmaceutical-market 2025-06-04T12:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/elpis-biopharmaceuticals-partners-with-singapore-general-hospital-to-advance-next-generation-car-gdt-therapies-for-blood-cancers 2025-06-04T12:57:49+00:00 hourly 0.9 https://trial.medpath.com/news/m42-astrazeneca-and-sophia-genetics-launch-uae-liquid-biopsy-initiative-to-transform-cancer-diagnosis 2025-06-04T12:57:29+00:00 hourly 0.9 https://trial.medpath.com/news/leon-nanodrugs-appoints-dr-wolfgang-hofmann-as-ceo-to-drive-nanoparticle-manufacturing-technology-commercialization 2025-06-04T12:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/wildtype-becomes-first-company-to-launch-cultivated-seafood-in-us-market-following-fda-clearance 2025-06-04T12:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-health-and-axxam-form-strategic-partnership-to-accelerate-ai-driven-drug-target-discovery 2025-06-04T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/saniona-advances-neurological-pipeline-with-strategic-partnerships-and-strong-financial-position 2025-06-04T12:56:20+00:00 hourly 0.9 https://trial.medpath.com/news/patent-settlements-accelerate-generic-and-biosimilar-market-entry-generating-423-billion-in-healthcare-savings 2025-06-04T12:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-to-present-novel-captn-3-tri-specific-antibody-platform-at-eacr-2025 2025-06-04T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-trials-launches-remote-telehealth-pre-screening-to-expand-access-for-regional-patients 2025-06-04T10:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/traws-pharma-stock-surges-94-following-breakthrough-drug-trial-success 2025-06-04T10:56:33+00:00 hourly 0.9 https://trial.medpath.com/news/ai-guided-drug-discovery-identifies-promising-cancer-treatment-combinations-using-existing-non-cancer-medications 2025-06-04T09:56:23+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-drug-combination-outperforms-keytruda-in-advanced-lung-cancer-trial 2025-06-04T09:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-launches-automated-strem2-assay-to-advance-neuroinflammation-research-in-alzheimer-s-disease 2025-06-04T09:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-advances-bi-1910-anti-tnfr2-antibody-with-population-modeling-data-at-page-2025 2025-06-04T09:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/caltech-s-smart-bandage-technology-demonstrates-early-biomarker-detection-in-first-human-clinical-trial 2025-06-04T09:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/abl-diagnostics-unveils-advanced-hiv-drug-resistance-detection-platform-at-european-meeting 2025-06-04T08:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/synact-pharma-secures-sek-30-million-credit-facility-to-advance-rheumatoid-arthritis-drug-development-through-mid-2026 2025-06-04T08:59:52+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-clinical-trial-targets-treatment-resistant-ibs-in-groundbreaking-gastroenterology-study 2025-06-04T06:54:58+00:00 hourly 0.9 https://trial.medpath.com/news/akadeum-life-sciences-secures-20m-to-advance-cell-separation-technology-for-gene-and-cell-therapy-manufacturing 2025-06-04T04:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-licenses-pde4-inhibitor-itg-1052-for-idiopathic-pulmonary-fibrosis-treatment 2025-06-04T01:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-promise-for-adjuvant-braf-mek-inhibitor-combination-in-high-risk-melanoma 2025-06-04T00:58:58+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-immunotherapy-shows-unprecedented-five-year-survival-in-advanced-multiple-myeloma-patients 2025-06-04T00:58:47+00:00 hourly 0.9 https://trial.medpath.com/news/computer-modeling-identifies-two-broad-spectrum-antiviral-compounds-against-rna-viruses 2025-06-04T00:57:59+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-advances-phase-2-trial-of-novel-ipf-drug-bersiporocin-with-diverse-patient-population 2025-06-04T00:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-agrees-to-placebo-controlled-trial-for-new-covid-19-vaccine-following-fda-approval 2025-06-04T00:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-emerges-as-powerful-prognostic-biomarker-in-locally-advanced-cervical-cancer 2025-06-04T00:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/asco-2025-showcases-advances-in-myelofibrosis-treatment-with-novel-jak-inhibitors-and-personalized-approaches 2025-06-04T00:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/essential-thrombocythemia-market-set-for-significant-growth-as-novel-therapies-enter-pipeline 2025-06-04T00:56:10+00:00 hourly 0.9 https://trial.medpath.com/news/ascletis-first-in-class-acne-drug-denifanstat-meets-all-phase-iii-endpoints-outperforms-fda-approved-treatments 2025-06-04T00:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/redwire-secures-contract-with-aspera-biomedicines-for-space-based-cancer-research-using-adar1-inhibitor-rebecsinib 2025-06-04T00:52:24+00:00 hourly 0.9 https://trial.medpath.com/news/aravax-strengthens-leadership-team-with-regulatory-expert-louise-peacock-ahead-of-phase-3-peanut-allergy-trial 2025-06-03T22:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/camurus-and-eli-lilly-forge-870-million-partnership-for-long-acting-diabetes-and-obesity-therapies 2025-06-03T21:54:11+00:00 hourly 0.9 https://trial.medpath.com/news/congruence-therapeutics-advances-cgx-926-for-rare-genetic-obesity-as-company-presents-novel-mc4r-corrector-data 2025-06-03T21:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-pivots-molecular-diagnostics-strategy-with-100m-lex-diagnostics-acquisition 2025-06-03T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/us-court-allows-lupin-and-zydus-to-expand-patent-defense-arguments-in-myrbetriq-generic-drug-case 2025-06-03T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/dante-trial-shows-promise-for-shorter-immunotherapy-duration-in-advanced-melanoma 2025-06-03T20:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/huntington-s-disease-pipeline-shows-robust-growth-with-20-companies-developing-novel-therapies 2025-06-03T20:57:34+00:00 hourly 0.9 https://trial.medpath.com/news/aspaveli-demonstrates-sustained-68-proteinuria-reduction-in-phase-3-valiant-trial-for-rare-kidney-diseases 2025-06-03T20:57:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-darolutamide-for-metastatic-castration-sensitive-prostate-cancer-based-on-aranote-trial-results 2025-06-03T20:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/leyden-labs-secures-eur20-million-eib-funding-to-advance-pan-influenza-nasal-spray-development 2025-06-03T19:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-launches-phase-2a-trial-of-delgocitinib-cream-for-rare-skin-disease-palmoplantar-pustulosis 2025-06-03T18:53:49+00:00 hourly 0.9 https://trial.medpath.com/news/brain-training-game-shows-promise-for-drug-free-nerve-pain-treatment-in-first-clinical-trial 2025-06-03T18:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-partners-with-dcm-foundation-to-advance-bag3-dilated-cardiomyopathy-awareness-and-genetic-testing 2025-06-03T18:51:15+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-to-present-briquilimab-clinical-data-at-eaaci-congress-2025 2025-06-03T17:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-exclusive-rights-to-agenus-bot-bal-cancer-immunotherapy-for-india-and-sri-lanka 2025-06-03T17:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/antheia-secures-56m-series-c-to-scale-synthetic-biology-platform-for-critical-drug-manufacturing 2025-06-03T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-discontinues-psoriasis-and-eczema-drug-scd-044-after-phase-2-trial-failures 2025-06-03T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/russia-s-personalized-mrna-cancer-vaccine-set-for-clinical-launch-by-october-2025 2025-06-03T17:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/allergan-botox-patent-infringement-trial-against-revance-set-for-july-in-delaware 2025-06-03T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/patent-trial-and-appeal-board-institutes-review-against-halozyme-in-merck-patent-dispute 2025-06-03T17:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/trexbio-initiates-first-in-human-trial-of-trb-061-novel-tnfr2-agonist-for-atopic-dermatitis 2025-06-03T17:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/ocu410-gene-therapy-shows-promise-for-geographic-atrophy-with-single-dose-treatment-approach 2025-06-03T17:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/mentaily-secures-3m-seed-funding-for-ai-powered-mental-health-diagnostic-platform-liv 2025-06-03T17:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-secures-500-million-credit-facility-to-support-atacicept-commercial-launch 2025-06-03T17:00:10+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-expands-apj-agonist-pipeline-with-novel-oral-and-injectable-candidates-for-enhanced-obesity-treatment 2025-06-03T16:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/reshape-lifesciences-achieves-early-eu-mdr-certification-for-obesity-treatment-devices 2025-06-03T16:59:01+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-receives-fda-orphan-drug-designation-for-beam-101-sickle-cell-disease-therapy 2025-06-03T16:58:59+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-temab-a-adc-shows-63-response-rate-in-egfr-mutated-nsclc-phase-i-trial 2025-06-03T16:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/amplitude-trial-shows-niraparib-combination-reduces-cancer-progression-risk-by-37-in-hrr-mutant-metastatic-prostate-cancer 2025-06-03T16:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-sarclisa-shows-non-inferior-efficacy-with-novel-on-body-injector-in-phase-3-multiple-myeloma-trial 2025-06-03T15:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/matter-neuroscience-partners-with-stanford-medicine-to-test-novel-fmri-guided-depression-therapy 2025-06-03T13:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-appoints-dr-william-andrews-as-chief-medical-officer-to-lead-rare-disease-strategy 2025-06-03T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/flot-chemotherapy-demonstrates-superior-survival-and-distant-recurrence-control-over-cross-in-esophageal-adenocarcinoma 2025-06-03T13:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-trans-amplifying-mrna-vaccine-platform-with-40-fold-dose-reduction-and-broad-viral-protection 2025-06-03T12:57:12+00:00 hourly 0.9 https://trial.medpath.com/news/minerva-biotechnologies-advances-muc1-targeted-car-t-therapy-with-1xx-mutations-for-solid-tumors 2025-06-03T12:56:43+00:00 hourly 0.9 https://trial.medpath.com/news/kamari-pharma-secures-23-million-series-a-to-advance-first-in-class-trpv3-inhibitor-for-rare-genetic-skin-diseases 2025-06-03T12:55:49+00:00 hourly 0.9 https://trial.medpath.com/news/rigosertib-achieves-80-response-rate-in-first-clinical-trial-for-rare-rdeb-associated-skin-cancer 2025-06-03T12:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-launch-final-phase-trial-of-bromocriptine-for-familial-alzheimer-s-disease 2025-06-03T12:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/markherz-partners-with-tum-hospital-to-advance-aav-gene-therapy-for-cardiovascular-disease 2025-06-03T12:53:55+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-s-radioligand-therapy-177lu-sn201-advances-in-phase-i-iia-trial-following-positive-safety-review 2025-06-03T12:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-receives-cdsco-approval-for-liraglutide-diabetes-drug-in-india 2025-06-03T09:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/jade-biosciences-to-present-preclinical-data-on-jade101-anti-april-antibody-for-iga-nephropathy-at-european-renal-congress 2025-06-03T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-advances-aversa-fentanyl-abuse-deterrent-patch-development-with-kindeva-partnership 2025-06-03T07:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/spyglass-pharma-secures-75-million-series-d-to-advance-long-term-glaucoma-drug-delivery-platform-through-phase-iii-trials 2025-06-03T06:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/sony-screen-and-vitrovo-launch-high-density-mea-system-trial-for-drug-discovery-and-neurological-disease-research 2025-06-03T05:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-lymphoma-in-preclinical-studies 2025-06-03T04:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/amivantamab-shows-promise-in-colorectal-cancer-as-phase-3-trials-launch-following-encouraging-phase-1b-2-results 2025-06-03T04:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-biomarker-and-prognostic-framework-emerges-for-attr-cm-disease-monitoring 2025-06-03T02:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-authorization-for-ai-platform-to-predict-breast-cancer-risk-from-mammograms 2025-06-03T01:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-partners-with-foresight-diagnostics-and-tracer-biotechnologies-to-expand-minimal-residual-disease-testing-portfolio 2025-06-03T01:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/trastuzumab-deruxtecan-combination-reduces-disease-progression-risk-by-44-in-her2-positive-metastatic-breast-cancer 2025-06-03T00:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-belantamab-mafodotin-maintains-efficacy-in-high-risk-multiple-myeloma-patients-despite-treatment-withdrawal 2025-06-03T00:57:19+00:00 hourly 0.9 https://trial.medpath.com/news/extended-low-dose-apixaban-reduces-vte-recurrence-by-87-in-high-risk-patients 2025-06-03T00:55:23+00:00 hourly 0.9 https://trial.medpath.com/news/immuneoncia-s-cd47-antibody-imc-002-shows-30-response-rate-in-advanced-hepatocellular-carcinoma-trial 2025-06-03T00:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/merck-explores-3-billion-acquisition-of-swiss-biotech-moonlake-immunotherapeutics 2025-06-03T00:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-and-beckley-psytech-announce-390-million-merger-to-create-psychedelic-mental-health-leader 2025-06-03T00:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibody-drug-conjugate-achieves-85-response-rate-in-rare-blood-cancer-trial 2025-06-03T00:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/allogeneic-cell-therapies-emerge-as-next-generation-cancer-treatment-to-address-manufacturing-and-cost-challenges 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/jenscare-reports-positive-clinical-outcomes-for-tricuspid-and-mitral-valve-interventions-at-europcr-2025 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-submits-low-dose-mri-contrast-agent-gadoquatrane-for-global-regulatory-approval 2025-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/freenome-s-blood-based-colorectal-cancer-test-achieves-landmark-results-in-largest-prospective-study 2025-06-02T23:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/biocartis-achieves-first-ivdr-class-c-companion-diagnostic-certification-for-egfr-mutation-test-in-europe 2025-06-02T22:54:10+00:00 hourly 0.9 https://trial.medpath.com/news/vantive-announces-1-billion-investment-in-digital-kidney-care-technologies-over-five-years 2025-06-02T22:53:24+00:00 hourly 0.9 https://trial.medpath.com/news/rly-2608-shows-promise-in-pik3ca-mutant-breast-cancer-with-improved-tolerability-profile 2025-06-02T21:53:51+00:00 hourly 0.9 https://trial.medpath.com/news/curogen-appoints-industry-veteran-arvind-sood-as-global-coo-to-lead-us-expansion-of-nanotechnology-based-autoimmune-therapies 2025-06-02T21:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/protara-therapeutics-appoints-william-conkling-as-chief-commercial-officer-to-lead-commercialization-strategy 2025-06-02T21:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-data-show-lasting-survival-benefits-from-single-dose-til-therapy-in-advanced-melanoma 2025-06-02T21:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-high-throughput-lectin-based-screening-method-to-optimize-sialic-acid-glycosylation-in-drug-development 2025-06-02T20:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/frontage-laboratories-expands-manufacturing-capabilities-with-new-46300-sq-ft-crdmo-facility-in-pennsylvania 2025-06-02T20:56:43+00:00 hourly 0.9 https://trial.medpath.com/news/rebecsinib-becomes-first-space-tested-cancer-drug-to-enter-clinical-trials 2025-06-02T20:56:24+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-lenvima-combination-therapy-receives-chinese-approval-for-unresectable-hepatocellular-carcinoma 2025-06-02T19:53:43+00:00 hourly 0.9